

CURRICULUM VITAE

Robert J Chilton

GENERAL INFORMATION

PERSONAL DATA:

Date of Preparation: 5/21/2022

Address: 7400 Merton Minter
San Antonio, TX 78284

Phone Number: (210) 5677777

Fax Number:

Email Address: CHILTON@UTHSCSA.EDU

EDUCATION:

<u>Year</u>	<u>Degree</u>	<u>Discipline</u>	<u>Institution/Location</u>
1972	DO	Medicine	University of Osteopathic Medicine and Surgery, Des Moines, IA
1968	BS	Biology/Physics	Phillips University, Enid, OK

TRAINING:

Post Doctoral Fellowship

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1975-1978	Cardiology	Wilford Hall USAF, San Antonio, TX

Residency

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1973-1975	Medicine Residency	University of Oklahoma, Oklahoma City, OK
1972-1973	Internal Medicine/Internship	Wright Patterson AFB, Dayton, OH

ACADEMIC APPOINTMENTS:

Chairman of National ACOI Board of Examiners for interventional cardiology

March 2019- Associate Program Director Interventional Cardiology

March 2006-Present Professor of medicine University of Texas Health Science Center,
Department of Medicine, San Antonio, TX

01/1986 – Feb 06	Associate Professor of medicine	University of Texas Health Science Center, Department of Medicine, San Antonio, TX
01/1980 - 01/1986	Assistant Professor	University of Texas Health Science Center, Department of Medicine, San Antonio, TX
01/1980 - 01/1983	Associate Professor	Uniformed Services Medical School, Department of Medicine
01/1978 - 01/1980	Instructor	University of Texas Health Science Center, Department of Medicine, San Antonio, TX

NON-ACADEMIC APPOINTMENTS:

07/2014- Present	Director Clinical Proteomics Research NHLBI-UTHSCSA	
01/2009- Present	Medical Director: Invasive Cardiopulmonary Technicians Training St Phillips College: San Antonio, Texas	
01/2003 - Present	Cardiology Consultant to NASA	
01/1999 - Present	Director of Catheterization Lab AM	UTHSCSA, San Antonio, TX
01/1986 - Present	Director of Electrophysiology Lab AM	UTHSCSA, San Antonio, TX
01/1982 - 01/1986	Private Practice Electrophysiology/Interventional Cardiology	
01/1978 - 01/1982	Consultant to the AOA on Cardiovascular Rehabilitation USAF	USAF
01/1978 - 01/1982	Cardiology Consultant for Department of Defense (TRIMMIS)	USAF
01/1978 - 01/1982	Member, Wilford Hall USAF Resident/Intern Interviewing	USAF
01/1979 - 01/1982	Director of Cardiac Rehabilitation Program USAF	USAF
01/1979 - 01/1982	Education Coordinator for Cardiology Service USAF	
01/1979 - 01/1982	Visiting Cardiology Consultant for USAF	USAF
01/1979 - 01/1982	Director of 916 cardiopulmonary Training Program USAF	

CERTIFICATION AND LICENSURE:

Board Certification

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
Clinical Interventional Cardiology	Certified	11/2002	available upon request	n/a
Clinical Cardiac Electrophysiology	Certified	10/1995	available upon request	n/a
Cardiovascular Diseases/Cardiovascular Diseases	Certified	07/1979	available upon request	n/a

Certification

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
Affiliate Faculty/BCL Regional Faculty ACLS Provider - American Heart Association	Certified	Current	available upon request	available upon request
Controlled Substance Registration Certificate - Drug Enforcement of Administration (DEA) United States Department of Justice	Certified	Current	available upon request	available upon request
Texas Controlled Substances Registration Certificate - Texas Department of Public Safety	Certified	Current	available upon request	available upon request
Medical License - Texas State Board of Medical Sponsors	Certified	Current	available upon request	available upon request

TEACHING**COURSE BASED TEACHING:**

<u>Date</u>	<u>Course Name</u>	<u>Level</u>	<u>Role</u>
05/2022	Hyperlipidemia Medical student lecture	Graduate	
07/2018	Dyslipidemia	Post	
07/2018	Physical diagnosis course	Graduate	
05/2017	Hyperlipidemia	Post	
07/2017	Atherosclerosis	Graduate	
03/2017	Endocrinology, Diabetes, Metabolism	Post	
		Graduate	
		Post	

03/2016	Hypertension	Graduate
03/2016	Cardiac physical diagnosis course	Post Graduate
08/1999- Current	Cardiology Fellow Teaching Lectures	Post Graduate Post Graduate
08/1999 - Current	MEDI4077 Ekg/Heart Sound Rotation	Post Graduate

Preparation Hrs: 12, Student Contact Hrs: 4

Honors

Chairman national Board of examiners for interventional cardiology 2022 ACOI

2019 AHA grants committee for cardiometabolic disease

Chairman 2019 National board of examiners for interventional cardiologist

Associate program director for interventional cardiology

2014 Interventional Cardiology Outstanding Teaching Award, University of Texas Health Science Center

Researcher of the Year AOA/ACOI 2009

Outstanding Teacher Award from Internal Medicine Residents 1980 Wilford Hall USAF Medical Center

USAF Teacher Designation

Outstanding Teacher Award from senior medical student class 1994, University of Texas Health Science Center

Co-Chairman National AHA NPAM/EPI meeting March @2008

Director of clinical proteomics center NHLBI
UTHSCSA

RESEARCH

Protocol #: HSC20190077X

Title: Molecular Transducers of Physical Activity Consortium (MoTrPAC) CTMS#: CTMS 19-0025

OCR Analyst: DaNeisha Smith, Chilton

Effect of SGLT2i on LVEF in Type 2 Diabetic Patients with Acute MI

Beta-hydroxybutirate with cardiac MRI and PET based on the “ketone hypothesis” and the findings on decrease in cardiovascular death in the EMPA-REG and CANVAS studies.

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial (DAL-301)

Emboic considerations with the IMPELLA ventricular assist device

A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction (LCZ696B2320)

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

GRANT TITLE: GRADIENT OF INFLAMMATION IN VESSEL WALL ASSOCIATED WITH ATHEROSCLEROTIC PLAQUE (VT AZ MEDI ISSEXEN0012)

Protocol Number NC14983A. A comparison of the effects of Mibefradil vs Placebo for 3 weeks in patients with chronic stable angina pectoris. 1994-96

D-Sotalol in Treatment of Atrial Fibrillation. 1994-1998

D-Sotalol in Non-sustained Ventricular Tachycardia. 1994-1998

IV D-Sotalol in Ventricular Tachycardia. 1994-1998

South West Atherosclerosis Trial (SWAT). 1994-1998

Survival With Oral D-sotalol (SWORD). 1994-1998

Mortality Associated with Congestive Heart Failure (MACH-1). International Survival Trial. 1994-1998

Treat Angina with Aggrastat and determine cost of therapy with an Invasive or Conservative strategy (TACTICS-TIMI-18) 1988

Azimilide Post Infarction Survival Evaluation (ALIVE) 1998

Atherectomy before MultiLink Improves Lumen Gain and Clinical Outcome (AMIGO) 1998

Controlled Abciximab and Device Investigator to Lower Late Angioplasty Complications (CADILLAC) 1998

Stent Implantation Post Rotational Atherectomy Trial (SPORT) 1998

The second optimal stent Implantation Study II (OSTI-II) 1998

VA Cooperative Study # 385. Urgent Revascularization in Unstable Angina 1998 ongoing

CADILLAC: Randomized comparison of the ACS Multi-Link Duet with or without Abciximab vs PTCA with or without Abciximab in the treatment of patients with acute MI. 1999

AMIGO: Angiographic restenosis between the ACS Multi-Link with or without DCA in de novo and restenotic native coronary artery lesions 1999

BETA-CATH: Evaluate the safety and effectiveness of 90 Strontium vs Placebo in De novo and restenotic lesions of native coronary arteries 1999

r-FBF-2 (CHIRON): Evaluate safety, pharmacokinetics and efficacy of 3 doses of rFGF-2 vs placebo in patients with coronary artery disease. 1999

MCC135:Phase 2a safety and tolerability of 500 mcg/kg in patients with heart failure due to LV dysfunction 1999

REVERSAL: 18 months of treatment of atorvastatin or pravastatin on coronary artery disease using IVUS imagine of coronaries. 1999

HEDGEHOG: Hedgehog burr testing on native coronary artery disease compared to current Rotablator system. 1999

PRESTO: Clinical event rate trial on Tranilast to Placebo during 9 month follow up in patients having interventions 1999

CREDO: Double blind randomized trial of clopidogrel and asa in patients with coronary artery disease having interventional procedure. 1999

PILOT: Safety and efficacy of treatment with the EndiCOR X Sizer during treatment of SVG and native coronary artery lesions suspected of thrombus. 1999

A Safety and Dose Finding Study of Coronary Vascular Responses to MRE0470 after PTCA 2000

Phase II Multicenter, Double Blind, Placebo Controlled Dose Finding Study for Recombinant Fibroblast Growth Factor-2 (rFBF-2) in CAD 2000

Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications 2000

Biocompatibles BiodivYsio Stent Randomized Controlled Trial (DISTINCT)2000

Medtronic AVE High Scaffolding SVG Registry 2000

Stent Implantation Post Rotational Atherectomy Trial Sport Trial 2000

A prospective, randomized, placebo controlled, triple masked trial to evaluate safety of Novoste Beta-Cath System in the Treatment of In-stent restenosis (START) 2000

ENTIRE – TIMI 23: A phase II Stratified, Randomized Open Label Angiographic Trial to Assess safety of Enoxaparin as an Adjunct to Thrombolytics with GP 2b/3a in AMI 2000

X-Sizer for Treatment of Thrombus and Atherosclerosis in Coronary Intervention Trial 2000

A prospective randomized double blind multi-center Trial comparing Atorvastatin vs Pravastatin on Progression of CAD by IVUS (REVERSAL) 2000

SAGE -- Study assessing goals in elderly 2001

NHLBI- Clinical Outcomes Utilizing Revascularization and Drug Evaluation (COURAGE) ongoing 2001

NHLBI- Bypass Angioplasty Revascularization Investigation-BARI-2D (Diabetes) ongoing 2001

SYNERGY – A prospective randomized open label multi-center trial in patients presenting with acute coronary syndromes (ACS) 2001

A- Z Trial Project number 696 (Acute Coronary Syndrome) Aggrstat to Zocor 2001

BETACATH-Radiation to Instent Restenosis of Coronary Artery 2001

BRITE II-Beta radiation to reduce instent restenosis 2001

CORLOPAM Trial – Renal insufficiency patients have coronary artery interventions 2001

Filter Wire-SVG Transluminal intervention 2001

HIPS- Heparin infusion prior to stenting 2001

LARS-Laser angioplasty for restenosis of stents 2001

TIMI 23 Phase 2 Stratified Randomized Open Labeled Angiographic Trial to assess Safety and Efficacy of Enoxaparin as Adjunct to Thrombolytic Therapy 2001

EXSIZER for treatment of thrombus and atherosclerosis in coronary interventional trials 2001

SWING-sound wave inhibition for neointimal hyperplasia 2002

CARP Trial-Severe Vascular Disease and Revascularization 2002

A Prospective, Multicenter, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Integrated Vascular Systems Arterial Closure Device Versus Standard Compression 2002

A randomized comparison of Angiomax® (bivalirudin) versus Lovenox®/Clexane® (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation 2002

CardioShield Application Protects During Transluminal Intervention of Vein Grafts by Reducing Emboli 2002

A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BO-653 in the Prevention of Post-Angioplasty Restenosis in Stented Lesions: THE PREVAIL STUDY. Protocol BO-004 2002

Coral Registry Coronary Grafts Results following Atherectomy with Laser 2002

Complex Bifurcation Atherectomy Trial 2002

Patient Informed Consent Form for Participation In JOMED JOSTENT® SVG BARRICADE Trial (The Barrier Approach to Restenosis: Restrict Intima and Curtail ADverse Events) 2003

A Randomized, Double-blind Placebo-controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2(rNAPc2), in Subjects with Non-ST-Elevation Acute Coronary Syndromes-[ANTHEM (Anticoagulation with NAPc2 To Help Eliminate MACE)/TIMI 32] 2003

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease using Intravascular Ultrasound (IVUS) 2003

Across – CYPHER - Approaches to Chronic Occlusion with Sirolimus Stents – Cypher® (ACROSS-Cypher®) 2003

ACUITY (NSTEMI/ACS) IRB # 034-5001-318:

A randomized comparison of Angiomax® (bivalirudin) versus Lovenox®/Clexane® (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation 2003

ANTHEM (NSTEMI/ACS) IRB # 023-5001-077:

A Randomized, Double-blind Placebo-controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2(rNAPc2), in Subjects with Non-ST-Elevation Acute Coronary Syndromes-[ANTHEM (Anticoagulation with NAPc2 To Help Eliminate MACE)/TIMI 32] 2003

Capture (Carotid) IRB # 045-5001-169:

A post-approval study of the Guidant Acculink stent systems and AccUNET embolic protection systems (Carotid RX ACCULINK/ACCUNET Post- Approval Trial to Uncover Unanticipated and Rare Events – “CAPTURE”) 2003

CLOSURE I (PFO) IRB # 034-5001-146:

A Prospective, Multicenter, Randomized, Controlled Trial To Evaluate The Safety And Efficacy Of The Starflex® Septal Closure System Versus Best Medical Therapy In Patients With A Stroke And/Or Transient Ischemic Attack Due To Presumed Paradoxical Embolism Through A Patent Foramen Ovale 2003

EARLY ACS (Integrilin) (NSTEMI/ACS) IRB # 045-5001-034:

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) 2004

EVEREST I (MV-Clip - MR) IRB # 034-5001-436:

Endovascular Valve Edge-To Edge Repair Study (EVEREST I) 2004

Pfizer IRB # 034-5001-076:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease using Intravascular Ultrasound (IVUS) 2004

STRADIVARIUS (IVUS/ Rimonabant) IRB # 045-5001-116:

Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant – The Intravascular Ultrasounds Study (STRADIVARIUS) 2004

TRIUMP (Unstable AMI) Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock (TRIUMPH) 2004

APPROACH - (Diabetic-IVUS-Rosiglitazone) A Phase III, 18-month, Multicenter, Randomized, Double-Blind, Active Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease 2004

WATCHMAN® Left Atrial Appendage Filter System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) IRB # 045-5001-154: ® Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF). 2004

PERISCOPE (IVUS - ACTOS - DM)

“A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HC versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultrasound.” – “PERISCOPE” 2004

JOSTENT (Registry) IRB # 034-5001-376:

Use of Humanitarian Device, the JOESTENT® Graft Master Coronary Stent Graft 2004

Proximal Protection during Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System: A Randomized, Prospective, Multicenter Clinical Trial. 2004

TENACITY (PCI- tirofiban vs. abciximab)

A Randomized, Multicenter, Double-Blind, Abciximab-Controlled Study to Evaluate the Efficacy of Tirofiban versus Abciximab among Subjects Undergoing Percutaneous Coronary Intervention with Stent Placement Receiving Bivalirudin or Heparin (TENACITY). Protocol number: 0120-0401 IND# 38899 2004

Clip: A Prospective, Multicenter, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Integrated Vascular Systems Arterial Closure Device Versus Standard Compression, Protocol 640-0041-04 2004

Barricade IRB # 012-5001-314 2005

MERLIN (Ranolazine - NSTEMI/ACS)

Randomized, Double Blind, Parallel-Group, Placebo-Controlled Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine versus Placebo in Patients with Non-ST Segment Elevations Acute Coronary Syndromes. – MERLIN - (CVT # 3036) 2004

Security IRB # 012-5001-192 2005

ACTIVATE

A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of the ACAT Inhibitor CS505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease using Intravascular Ultrasound (IVUS) 2004

Prevail (IRB # 012-5001-032) 2005

COMBAT IRB # 023-5001-062 2005

VOLCANO Registry (IVUS) IRB # 045-5001-067 2005

CORAL Registry: Coronary Graft Results Following Atherectomy with Laser 2005

CoStar II

A Prospective, Multicenter, Two-Arm, Randomized, Controlled, Trial of the Conor Costar Paclitaxel-Eluting Coronary Stent System versus the Taxus Drug-Eluting Coronary Stent System in Patients with DeNovo Lesions of the Native Coronary Arteries 2005

RADAR Pending 2005

Competent Pending 2005

EVOLVE (MCC-135) A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Standard Therapy with Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction 2005

2006

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease using Intravascular Ultrasound (IVUS) (**ACTIVATE**)

A Randomized, Double-blind Placebo-controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2(rNAPc2), in Subjects with Non-ST-Elevation Acute Coronary Syndromes-[ANTHEM (Anticoagulation with NAPc2 To Help Eliminate MACE)/TIMI 32] (**ANTHEM**)

A randomized comparison of Angiomax® (bivalirudin) versus Lovenox®/Clexane® (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation (**ACUITY**)

A Post –Approval Study of the Guidant Acculink Stent Systems and Accunet Embolic Protection System (**CAPTURE**)

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (**EARLY ACS**)

Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant – The Intravascular Ultrasounds Study (**STRADIVARIUS**)

Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock (**TRIUMPH**)

A Phase III, 18-month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (**APPROACH**)

A comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who are to Undergo Percutaneous Coronary Intervention' TIMI-38; H7T-MC-TAAL is a Phase 3, Multicenter, Randomized, Parallel-Group, Double Blind, Double-Dummy, Active-Controlled Study in Subjects with Acute Coronary Syndrome (ACS), Who Are To Undergo Percutaneous Coronary Intervention (PCI).” (**TRITON**)

The Volcano Registry. (**VOLCANO**)

Jostent SVG Trial: - “A Prospective, Randomized Trial of Stenting in Diseased Saphenous Vein Grafts with the JoMed Jostent Coronary Stent Graft vs. Standard Stenting. (**BARRICADE**)

“A Randomized, Double Blind, Parallel-Group, Placebo-Controlled Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine versus Placebo in Patients with Non-ST Segment Elevations Acute Coronary Syndromes. – (**MERLIN**)

“A Double-Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCL versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular.” (**PERISCOPE**)

APPROACH - “A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease”

CURRENT – “*Clopidogrel optimal loading dose Usage to Reduce Recurrent Events*”

EARLY ACS - *Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)*

DIVERGE TRIAL - “*Drug Stent Intervention for Treating Side Branches Effectively*” (AXXESS Plus Stent with *Biolimus A9)

SWAT TRIAL - The SWAT Trial - **StarClose® SE Without Anatomical Limitations** - "A Prospective, Multicenter, Single Arm Study To Evaluate The StarClose® Vascular Closure System In High Risk Subjects Undergoing 5 & 6 Fr Diagnostic Catheterization Procedures

T- C WYRE - TAXUS Express² Stent vs. Cypher Stent - What's your Real Life Experience?

VA COOP study 557 IRB hsc20070710H Coronary Artery Revascularization in Diabetes Study

BARI 2D ongoing follow up

COURAGE ongoing follow up

IRS # HSC 20080040H Protocol No: P07-6330 (The CYPHER®ELITE™ Study) A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER®ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems

Start Date: 9/16/2008 IRB# HSC20080418H - SATURN STUDY: Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) A 104-week, randomized, double-blind, parallel group, multi-center Phase 111b study comparing the effects of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease (SATURN acronym composed of S(tudy A(theroma) (In T(ravascular) U(ltrasound R(osuvastatin) (Atorvastatin)

Cardiovascular Outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D) (VA Project #0003/HSC20100232H)

ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches)-Accepted Pending NIH funding

NHLBI Proteomic Center Award, Co-investigator

RESOLUTE US stent trial (n=1,399) is a large, prospective, multicenter, controlled single-arm trial with a primary endpoint of target lesion failure (TLF) at 12 months

CSI/Orbit study with Orbital Atherectomy System for coronary artery disease

OTAMIXABAN VS. UNFRACTIONATED HEPARIN+EPTIFIBATIDE IN ELDERLY PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN THE SEPIA-ACS1 TIMI 42 TRIAL

SYMPPLICITY HTN-3 is a single-blind, randomized controlled trial designed to evaluate the safety and effectiveness of renal denervation with the company's Symplicity catheter system in patients with resistant hypertension

A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary artery disease when added top optimal background therapy

Can hypothermia be incorporated into Primary Angioplasty for Heart Attack

A clinical evaluation of Medtronic Endeavor Resolute Zotarolimus-Eluting Stent

ACS patient randomized to Otamixaban or eptifibatide with unfractionated heparin

Educational Material

Chilton RJ, Medical student core curriculum 2017-2018 hyperlipidemia

Chilton RJ, Medical student core curriculum 2017 hypertension

Chilton RJ, Medical student core curriculum 2017 preventive cardiology

Chilton RJ, Medical student core curriculum 2016 hyperlipidemia

Chilton RJ, Medical student core curriculum 2016 hypertension

Chilton RJ, Medical student core curriculum 2016 preventive cardiology

Chilton RJ, ACOI national training module for cardiology 2013

Chilton RJ, Van Belle E, Cefalu WT, Ratner RE. Building New Strategies: Vascular Consequences of Diabetes. CD Rom Symposium Proceedings and Slide Resources AHA. CME Consultants July 2007

Chilton RJ. Cardiovascular disease in diabetics. 2004 Mar. p. 1-38. ([University of Teleconference Network](#)).

Chilton RJ. Cardiology [American Board of Internal Medicine Textbook](#) 2004:217-310

Chilton RJ. Treatment Considerations for the Vulnerable Plaque: Update [University of Texas Health Science Center](#) 2003 Mar:1-28.

Chilton RJ. Cardiology [American Board of Internal Medicine Textbook](#) 2003:313-413

Chilton RJ. Treatment for Stable Angina: Update [University of Texas Health Science Center](#) 2000 Feb:1-42

Chilton RJ. Treatment of Hyperlipidemia for the Practicing Physician University of Texas Health Science Center 2000 Mar:1-32.

Chilton RJ. Cardiology American Board of Internal Medicine Textbook 1999:241-429.

Chilton RJ. Pre-Op Evaluation for the Cardiac Patient for Non Cardiac Surgery. University of Texas Health Science Center 1999 Oct:1-38.

Chilton RJ. Hypertension Update JNC-6. Monograph. 1999 Mar. p. 1-30. (Teleconference Network of Texas).

Chilton RJ. Syncope. Monograph 1999 Jan. p. 1-16. (University of Texas).

Chilton RJ. Risk Factor Assessment in Clinical Practice 1999. p. 1-32. (Monograph).

Chilton RJ. Clinical Aspects of Endothelial Dysfunction 1997. p. 1-67. (UTHSCSA).

Chilton RJ. Atrial Fibrillation-use of antiarrhythmic drugs (Monograph). 1997

Chilton RJ. Endothelium from Bench to Bedside 1996. p. 1-45. (UTHSCSA).

Chilton RJ. Pressure Volume Loops and Clinical Disease: www.amplatz.uthscsa.edu 1995

Chilton RJ. Introduction to Molecular Cardiology 1995. p. 1-53. (UTHSCSA).

Chilton RJ. Aorta myocardial infarction-cellular etiologies. 1994 Nov. p. 1-54. (Monograph).

Chilton RJ. Advanced Arrhythmia Diagnosis and Management 1994 Feb. p. 1-4. (University of Texas).

Chilton RJ, Hibner C.. Clinical electrocardiography 1994 Feb. p. 1-63. (Textbook University of Texas Health Science Center).

Chilton RJ. Atrial Fibrillation-current use of anticoagulants 1994 Feb. p. 1-63. (Monograph).

Chilton RJ. Secondary Prevention after MI 1994 Feb. p. 1-67. (Monograph)

Chilton RJ. Plaque stabilization-lipids 1994 1994 Jan. p. 1-57. (Monograph).

Chilton RJ. Current update in CHF 1994 Jan. p. 1-38. (monograph).

Chilton RJ. Treatment of the acute MI 1994 Jan. p. 1-56. (Teleconference of Texas).

Chilton RJ. Current concepts in the treatment of atrial fibrillation. Monograph 1993 Nov. ([University of Texas](#)).

Chilton RJ. New directions in thrombolytic treatment. Monograph 1993 Nov. p. 1-29. ([University of Texas](#)).

Chilton RJ. Women and heart disease 1993 Nov. p. 1-32. ([Monograph](#)).

Chilton RJ. Treatment of the acute myocardial infarction in ICU. Monograph 1993 Aug. ([University of Texas Health Science Center](#)).

Chilton RJ. Evaluation and treatment of sudden cardiac death. Monograph 1993 Jul. p. 1-28. ([University of Texas](#)).

Chilton RJ. Hypertension guidelines: JNC-5. Monograph 1993 Jul. p. 1-21. ([Teleconference Network of Texas](#)).

Chilton RJ. Emerging perspectives in ACD inhibition: Focus on the VA patient. Monograph. 1993 Mar. p. 1-12. ([Philadelphia College of Pharmacy and Science](#).)

Chilton RJ. Therapeutic nutrition. 1993 Jan. p. 37-93. ([Chapter Low Sodium Diet in Hypertension](#)).

Chilton RJ, Rosas H, Hibner C.. Basic Electrophysiology 1992. p. 1-152. ([Textbook](#)).

Abstracts

LEFT VENTRICULAR MASS AND EXAGGERATED HYPERTENSIVE BP RESPONSE TO BRUCE EXERCISE STRESS TEST IN DIABETICS AND NONDIABETICS

Michael Balderas MD, Rene Oliveros MD, FASH, Joaquin Cigarroa MD, Joan Hecht RN, Daniel Lozano ET, Robert Chilton, DO 2018 AHA ASH

MASKED HYPERTENSION IS NOT ASSOCIATED WITH ORTHOSTATIC HYPERTENSION Joaquin Cigarroa MD, Rene A. Oliveros MD, FASH, Michael Balderas MD, Joan Hecht RN, Chris Baez, MIT and Benjamin Garza, MIT, Robert Chilton DO. 2018 AHA ASH

Ambulatory Blood Pressure Monitoring on Medical Residents Working Overnight: The influence of caffeine on systolic and diastolic pressure, pulse pressure, and nocturnal dipping patterns. Pratik Dalal MD, Divyashree Varma MD, Taleen Khalaf MD, Robert Chilton DO, FACC, Rene Oliveros MD, FASH American Society of Hypertension, 2016

Arterial Stiffness Determined from Ambulatory Blood Pressure Monitoring. Khalaf, Chilton RJ Journal of the American Society of Hypertension (JASH). May 2016

Chilton R, Crowe S, Lund SS, Johansen OE The sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type 2 diabetes 25th European Meeting on Hypertension and Cardiovascular Protection 2015

Chilton R, Crowe S, Lund SS, Johansen OE. Empagliflozin Reduces Systolic Blood Pressure in Dipper and Non-Dipper Patients with Type 2 Diabetes and Hypertension. European Society of HT June 2015

Neeland IJ, McGuire DK, Chilton B, Crowe S, Lund SS, Johansen OE. Impact of empagliflozin on anthropometry and markers of visceral adiposity in patients with type 2 diabetes: effects by age, sex, and degree of abdominal obesity. Scandinavian Society for the Study of Diabetes (SSSD) meeting 2015

Oscar Rivera, MD; Rene Oliveros, MD; Joan Finch, RN; Shuko Lee, MS; Robert Chilton, MD
Central aortic pulse pressure is a better predictor of vascular aging than brachial pulse pressure in normotensive subjects. American Society of Hypertension 2013

Peter Toth, Elaine Chiquette, Robert Chilton: "Treatment with Exenatide Twice Daily and Once Weekly is Associated With Favorable Lipid Subclass Changes in Patients with Abnormal Baseline Values" NLA 2012

Elaine Chiquette, Robert Chilton, Peter Toth, "Reduction in Estimated 10-Year Coronary Heart Disease Risk Using Reynolds Risk Score: A Post-Hoc Analysis of Exenatide-Treated Patients with Diabetes". NLA 2012

Jorge Plutzky, Robert Chilton, John Buse, C Still, C Burns, Dennis Kim. Weight Loss, Blood Pressure, Pulse, and Circadian Patterns with Naltrexone Sustained-release/Bupropion Sustained-release. ACC 2011

Chilton, Robert J; Jorge Plutzky; Whedy Wang; John Buse. Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart Failure, was accepted for poster presentation at Obesity 2011 - the 29th Annual Scientific Meeting of The Obesity Society, which will be held in Orlando, FL.

Nguyen Nguyen¹, Xiaolin Zhang¹, Yunji Wang¹, Galen Schimdt¹, Richard A. Lange², Robert J. Chilton², Hai-Chao Han³, Merry L. Lindsey², and Yu-Fang Jin¹. Targeting Myocardial Infarction-Specific Protein Interactions Using Computational Analyses. NHLBI Proteomics Centers 2nd Investigators' Meeting July 2011

Chilton R, Dat Do, Jitesh Vasadia, and Steven Bailey. Increased Late Event Rate in Diabetic Patients Undergoing Carotid Artery Stent Placement Compared to Non Diabetic Patients. JACC Feb 1, 2005;45:67A

Chilton R, Umesh Arora, Dat Do, and Jitesh Vasadia. Absence of Gender Effect on Late Outcomes after Carotid Artery Stent Placement. JACC Feb 1, 2005;45:67A

Chilton R, Jitesh V. Vasadia, Dat Do, and Steven Bailey. Marked Underutilization of Effective Therapies in Patients with Documented Cerebrovascular Disease. JACC. Feb 1, 2005;45:28A

Chilton RJ, Challapalli M., Zabalgoitia M.. Hemodynamic and Angiographic Determinants of B-type Natriuretic Peptide Elevation in Patients with Acute Coronary Syndromes 2003. (ACC).

Chilton RJ, Oliveros RA. A simplified method for obtaining aortic valve areas without the need for planimetry Regional Meeting of American College of Physicians 1983 Mar

Chilton RJ. Digitalis toxicity with concurrent use of Digoxin and quinidine. 1983 Mar. (American College of Physicians Regional Meeting).

Chilton RJ, Beckmann CH. Non-invasive estimation of pulmonary capillary wedge pressure by analysis of pulmonary blood flow distribution. 1983 Mar. (American College of Physicians, Regional Meeting).

Chilton RJ, Wilson C. Surprise survey of cardiac arrest carts in a large medical center. 1983 Mar. (Regional Meeting of American College of Physicians.).

Chilton RJ, Koppes GM. Segmental wall motion abnormalities with mitral valve prolapse. 1983 Mar. (Regional Meeting of American College of Physicians.).

Chilton RJ, Oliveros RA. Restrictive physiology following open heart surgery: Case report and review of the literature. 1983 Mar. (Regional Meeting of American College of Physicians.).

Chilton RJ, Boran K, Oliveros RA.. Pacemaker Selection based on electrophysiologic and hemodynamic criteria 1983. p. 4A. (Clin Res; vol. 31, no. 1).

Chilton RJ, Oliveros RA, Wiland F, Bechmann CH, Boran K.. The significance of the stress ejection fraction in the timing for surgery for aortic regurgitation. 1982. p. 210A. (Clin Res; vol. 30, no. 2).

Chilton RJ, Boran KJ, Oliveros RA, Beckmann CH.. A new criteria for the diagnosis of the angulated interventricular septum by M-mode echocardiography. 1982. p. 174A. (Clin Res; vol. 30, no. 2).

Chilton RJ, Beckmann CH. Arrhythmias during dental procedures: a study using ambulatory electrocardiograph Regional Meeting of American College of Physicians, San Antonio, Texas 1981 Mar

Chilton RJ, Boucher C. Ventricular function and coronary artery disease: the effect of isometric stress Regional Meeting of American College of Physicians, San Antonio, Texas 1981 Mar

Chilton RJ, Wilson C. Evaluation of cardiac resuscitation procedure at a medical center Regional Meeting of American College of Physicians, San Antonio Texas 1981 Mar

Chilton RJ, Boucher C. Isometric stress in aortic regurgitation: discriminatory effects on ventricular performance Regional Meeting of American college of Physicians, San Antonio, Texas 1981 Mar

Chilton RJ, Koppes GM, Oliveros RA. Sudden cardiac death during strenuous exercise Regional Meeting American college of Physicians, San Antonio, Texas 1981 Mar

Chilton RJ. Pulmonary artery origin of the left anterior descending coronary artery: a case report 1981 Mar. (Regional meeting of American College of Physicians, San Antonio, Texas).

Chilton RJ, Beckman CH, Oliveros RA, Parker SB.. The influence of heart rate on the myocardial supply demand ratio: an atrial pacing study. 1981. p. 644A. (Clin Res; vol. 29, no. 3).

Chilton RJ, Dlabal PW, Oliveros RA, Lasher L, Beckmann CH, Parker SB.. Noninvasive estimation of pulmonary capillary wedge pressure by analysis of pulmonary blood flow distribution. 1981. p. 691A. (Clin Res; vol. 29, no. A).

Chilton RJ, Boucher C, Beckmann CH. Usefulness of T201 scan with atrial pacing in a patient with coronary artery disease/ Regional meeting American College of Physicians, St, Louis Missouri. 1980 Mar

Chilton RJ, Jacobs R. Severe intensification of allergic anaphylactic reactions in patients on propranolol. Regional meeting American College of Physicians, St. Louis, Missouri 1980 Mar

Chilton RJ, Olivares RA, Beckmann CH. Q to peak of the murmur in aortic and pulmonic stenosis. Regional Meeting American College of Physicians, St. Louis, Missouri 1980 Mar

Chilton RJ, Boucher C, Beckmann CH. Usefulness of T201 scan with atrial pacing in a patient with coronary artery disease/ Regional meeting American College of Physicians, St. Louis Missouri. 1980 Mar

Chilton RJ, Grassman Ed, Olivares Ra, Dlabal PW. Comparison of angiographic single-plane and biplane ejection fraction with ejection fraction obtained by radionuclide angiography 1980. p. 176A. (Clin Res; vol. 28, no. 92).

Chilton RJ, Koppes G.. M-mode echocardiography in scleroderma Regional Meeting American College of Physicians, San Antonio, Texas 1979 Mar

Chilton RJ, Koppes GM, Frochlier V.. Serial oxygen consumption after acute myocardial infarction Regional Meeting American College of Physicians, San Antonio, Texas 1979 Mar

Chilton RJ, Olivares RA. Subendocardial blood flow as a correlate of the severity of aortic regurgitation. Regional ACP Meeting, San Antonio, Texas 1978 Feb

Electronic/Web Publication

Creatus: 2012: Review of AHA 2012 guidelines: Increasing obesity related thrombogenesis

Podcast Biocritique: 2008 Imaging and CV disease: where does it leave us?

iDOC: 2008 Podcast: High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese

Biocritique editorial 2008: Obesity, Behavioral Lifestyle Factors, and Risk of Acute Coronary Events

Biocritique editorial 2008: Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

iDOC: 2008 Podcast Insulin resistance and Cardiovascular Risk

Biocritique editorial 2008: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy

Podcast Biocritique: Statins in the Elderly 2008

Biocritique 2008 editorial: Niemann-Pick C1-Like 1 Is Required for an LXR Agonist to Raise Plasma HDL

Web alert quarterly publications 2008: Current Atherosclerosis Reports

Biocritique editorial 2008: Can metabolic syndrome predict cardiovascular disease?

Biocritique editorial 2008: Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events

Regulation of bone mass, bone loss, and osteoclast activity by cannabinoid antagonist August 2005. BioCritque.com

Effects of Acute Treatment With Pravastatin on Cerebral Vasospasm, Autoregulation, and Delayed Ischemic Deficits After Aneurysmal Subarachnoid Hemorrhage August 2005. BioCritque.com

Low-dose aspirin increases aspirin resistance in patients with coronary artery disease July 2005. BioCritque.com

Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study July 2005. BioCritque.com

Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control Results From the Pioneer Study June 2005. BioCritque.com

Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes May 2005. BioCritque.com

Effects of the PPAR γ agonist Pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. April 2005. BioCritque.com

Elevated Serum C-Reactive Protein Levels and Advanced Atherosclerosis in Youth April 2005. BioCritque.com

Physical Inactivity Increases Oxidative Stress, Endothelial Dysfunction, and Atherosclerosis April 2005. BioCritque.com

Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men. March 2005. BioCritque.com

Effect of Lipid-Lowering Therapy With Atorvastatin on Atherosclerotic Aortic Plaques Detected by Noninvasive Magnetic Resonance Imaging February 2005. BioCritque.com

Effect of Lipid-Lowering Therapy With Atorvastatin on Atherosclerotic Aortic Plaques Detected by Noninvasive Magnetic Resonance Imaging February 2005. BioCritque.com

Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery December 2004. BioCritque.com

Sirolimus-Eluting vs Uncoated Stents for Prevention of Restenosis in Small Coronary Arteries: A Randomized Trial. December 2004. BioCritque.com

High-Density Lipoprotein Stimulates Myocardial Perfusion: In Vivo November 2004. BioCritque.com

Bariatric Surgery: A Systematic Review and Meta-analysis October 2004. BioCritque.com

Angiotensin-converting enzyme 2 is an essential regulator of heart function August 2004. BioCritque.com

Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk. February 2003. BioCritque.com

Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation. December 2002. BioCritque.com

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. November 2002. BioCritque.com

Repeated Three-Dimensional Magnetic Resonance Imaging of Atherosclerosis Development in Innominate Arteries of Low-Density Lipoprotein Receptor-Knockout Mice August 2002. BioCritque.com

Kiesz RS, Rozek MM, Mego DM, Miller L, O'Leary E, Bailey RS, Saunders-Webb E, Ebersole DG, Chilton RJ. Device Synergy: Directional Atherectomy And Stenting Safely Eliminates Residual Stenosis 1996

Journal Article

Myocardial considerations in type 2 diabetes Chilton RJ. Journal of Diabetes doi: 10.1111/1753-0407.12788

Glucose Lowering and Vascular Protective Effects of Cycloset Added to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Chilton RJ, Endocrinology, Diabetes & Metabolism DOI: 10.1002/edm2.34

[SGLT2 inhibitors: a narrative review of efficacy and safety.](#)

Nelinson DS, Sosa JM, **Chilton RJ**. J Osteopath Med. 2021 Feb 1;121(2):229-239. doi: 10.1515/jom-2020-0153.PMID: 33567084 **Free article.**

[Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.](#)

Chilton RJ. Diabetes Obes Metab. 2021 May;23(5):1215-1218. doi: 10.1111/dom.14320. Epub 2021 Feb 26.PMID: 33464709 No abstract available.

□

[The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era.](#)

Vogt JC, Manning PG, Sheikh O, Aronow HD, **Chilton RJ**, Cigarroa JE. Catheter Cardiovasc Interv. 2021 May 1;97(6):1221-1229. doi: 10.1002/ccd.29089. Epub 2020 Jul 8.PMID: 32638540 No abstract available.

[Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.](#)

Chilton RJ, Dungan KM, Shubrook JH, Umpierrez GE. Prim Care Diabetes. 2020 Jun;14(3):193-212. doi: 10.1016/j.pcd.2019.09.008. Epub 2019 Nov 6. PMID: 31704161 **Free article.** Review.

[Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.](#)

Silva-Cardoso J, Sheikh O, Nashawi M, Pham S, Gallegos KM, Dinkha LR, **Chilton RJ**. J Diabetes. 2020 Apr;12(4):279-293. doi: 10.1111/1753-0407.13007. Epub 2019 Dec 11. PMID: 31688975 Review.

Cite

[Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.](#)

Chilton RJ. Diabetes Obes Metab. 2020 Jan;22(1):16-29. doi: 10.1111/dom.13854. Epub 2019 Aug 30. PMID: 31407866 Review.

[Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control.](#)

Clarke GD, Molina-Wilkins M, Solis-Herrera C, Mendez V, Monroy A, Cersosimo E, **Chilton RJ**, Abdul-Ghani M, DeFronzo RA. Endocrinol Diabetes Metab. 2018 Apr 6;1(2):e00014. doi: 10.1002/edm2.14. eCollection 2018 Apr. PMID: 30815550 **Free PMC article.**

[PCSK9 inhibitors and diabetes: Translational biology to clinical practice.](#)

Chilton RJ, Oliveros R, Gallegos KM, Pham S. Diabetes Obes Metab. 2019 Mar;21(3):451-453. doi: 10.1111/dom.13600. Epub 2019 Jan 17. PMID: 30520245 No abstract available.

[Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.](#)

Chilton RJ, Dungan KM, Shubrook JH, Umpierrez GE. Prim Care Diabetes. 2019 Nov 5. pii: S1751-9918(19)30075-0. doi: 10.1016/j.pcd.2019.09.008. [Epub ahead of print] Review. PMID:31704161

[Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.](#)

Silva-Cardoso J, Sheikh O, Nashawi M, Pham S, Gallegos KM, Dinkha LR, **Chilton RJ**.

J Diabetes. 2020 Apr;12(4):279-293. doi: 10.1111/1753-0407.13007

[Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.](#) Chilton RJ.

Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13854PMID: 31407866

PCSK9 inhibitors and diabetes: Translational biology to clinical practice.

Chilton RJ, Oliveros R, Gallegos KM, Pham S.

Diabetes Obes Metab. 2019 Mar;21(3):451-453.

Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.

Marso SP, Hardy E, Han J, Wang H, **Chilton RJ**.

Diabetes Ther. 2018 Apr;9(2):551-564

The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.

Chilton RJ, Gallegos KM, Silva-Cardoso J, Oliveros R, Pham S.

Curr Diab Rep. 2018 Nov 8;18(12):144.

Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control.

Clarke GD, Molina-Wilkins M, Solis-Herrera C, Mendez V, Monroy A, Cersosimo E, **Chilton RJ**, Abdul-Ghani M, DeFronzo RA.

Endocrinol Diabetes Metab. 2018 Apr 6

Anand Prasad MD¹, Vani P. Sanon MD¹, Saad S. Ghumman MD¹, Daniel B. Levin MD¹, Arnold H. Seto MD, MPA², Morton Kern MD², Robert Chilton DO¹, Subhash Banerjee MD³, Massoud Leesar MD⁴, William L. Henrich MD⁵ Invasive Hemodynamics in the Peripheral Arterial Circulation: Rationale, Physiology, and Emerging Clinical Data 2018 accepted

Dr Nelusha Shunmoogam¹, Dr Poobalan Naidoo¹, Prof Robert Chilton²

Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance

Vascular Health and Risk Management 2018;14 137-143

Lin, Charles Chilton, Robert. Clinical Perspective: Diabetes and Calcific Aortic Stenosis.

International Journal of Diabetology & Vascular Disease Research. 2018

New-onset heart failure in a patient after treatment with CBL0137, a curaxin-based chemotherapeutic agent. Ostrominski, John, Chilton, Robert. *Case Reports in Cardiology* 2018

Robert Chilton MD, Ilkka Tikkanen MD Uwe Hehnke Dipl | Hans J. Woerle MD

Odd Erik Johansen MD, PhD. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. *Diabetes Obes Metab.* 2017;1 – 5

Muhammad Abdul-Ghani, Ralph A. DeFronzo, Stefano Del Prato, Robert Chilton, Rajvir Singh and Robert E.J. Ryder. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care* 2017 Jul; 40 (7): 813-820

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E, **Chilton RJ**, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. *Diabetes Care.* 2017 Nov;40(11):1530-1536

Pham S, Chilton R. EMPA-REG OUTCOME: The Cardiologist ' s Point of View. *The American Journal of Medicine* 2017;130:57-62

ADA editorial board Chilton RJ, Standards of Medical Care in Diabetes 2017 *Diabetes Care* 2017;40:1-142

Anh Pham, Son Pham, Robert Chilton J Getting to the Heart of Diabetes: Translational Science to Interventional Cardiology. *J Diabetes Treat* 2017: J112.

Sanon VP, Patel Shalin, Sanon Saurabh, Rodriguez Rubin, Pham Son, Chilton Robert. Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of Empagliflozin. *Therapeutics and Clinical Risk Management.* 2017;13:603-611

Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, **Chilton R**, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. *Cardiovasc Diabetol.* 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.

Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. *Diabetes Obes Metab.* 2017 Apr 6. doi: 10.1111/dom.12962.

Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. *Cardiovasc Diabetol.* 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3

Abdul-Ghani M, Del Prato S, **Chilton R**, DeFronzo RA.

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. *Diabetes Care*. 2016 May;39(5):717-25. doi: 10.2337/dc16-0041.

DeFronzo RA, **Chilton R**, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. *Diabetes Obes Metab*. 2016 May;18(5):454-62. doi: 10.1111/dom.12652. Epub 2016 Apr 6.

Tikkanen I, **Chilton R**, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. *Curr Opin Nephrol Hypertens*. 2016 Mar;25(2):81-6.

Cardiac Manifestations of Congenital Generalized Lipodystrophy.

Sanon VP, Handelsman Y, Pham SV, Chilton R. Cardiac Manifestations of Congenital Generalized Lipodystrophy. *Clin Diabetes*. 2016 Oct;34(4):181-186

Neeland IJ, McGuire DK, **Chilton R**, Crowe S, Lund SS, Woerle HJ, Broedl UC.

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res*. 2016 Mar;13(2):119-26.

Ping Xu, Jeffrey P. Krischer, Lynch, R Chilton on behalf of the Type 1 Diabetes TrialNet Study Group Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes—A Recursive Partitioning Analysis. *Diabetes Care* April 2016

Ambulatory Blood Pressure Monitoring on Medical Residents Working Overnight: The influence of caffeine on systolic and diastolic pressure, pulse pressure, and nocturnal dipping patterns. Pratik Dalal, Divyashree Varma, Taleen Khalaf, Robert Chilton, Rene Oliveros. *Journal of the American Society of Hypertension (JASH)*. May 2016

Arterial Stiffness Determined from Ambulatory Blood Pressure Monitoring. Khalaf, Pratik Dalal MD, Divyashree Varma MD, Chilton RJ *Journal of the American Society of Hypertension (JASH)*. May 2016

The Influence of Shift Work on Systolic and Diastolic Blood Pressure, Pulse Pressure, and Dipping Patterns in Healthy Medicine Residents

Divyashree Varma MD, Pratik Dalal MD, Taleen Khalaf MD, Son Van Pham MD, Rene Oliveros MD, FASH. *Journal of the American Society of Hypertension (JASH)*. May 2016

Tamborlane WV, Haymond MW, Dunger D, Shankar R, Gubitosi-Klug R, Bethin K, Karres J, Tomasi P, Libman I, Hale PH, Portman R, Klingensmith G, Reed M, Blumer J, Giacoia G; NICHD Diabetes Working Group.. Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper From the NICHD Diabetes Working Group. *Diabetes Care*. 2016 Mar;39(3):323-9. doi: 10.2337/dc15-1649.

DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. *Diabetes Obes Metab.* 2016 May;18(5):454-62

A Randomised, Active- and Placebo-Controlled, Three-Period Crossover Trial to Investigate Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Macro- and Microvascular Endothelial Function in Type 2 Diabetes. Thomas Jax, Alin Stirban, Arne Terjung, Habib Esmaeili, Andreas Berk, Sandra Thiemann, Robert Chilton, Maximilian von Eynatten, Nikolaus Marx. *Cardiovascular Diabetology* 2016

Tikkanen, Ilkka; Chilton, Robert; Johansen, Odd Erik. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. *Current Opinion in Nephrology & Hypertension.* 25(2):81-86, March 2016.

Ian J Neeland, Darren K McGuire, Robert Chilton, Susanne Crowe, Søren S Lund⁴, Hans J Woerle⁴, Uli C Broedl⁴ and Odd Erik Johansen Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. *Diabetes & Vascular Disease Research* 2016, Vol. 13(2) 119–126

Expanding Treatment Options for Youth with Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper from the NICHD Diabetes Working Group. William V. Tamborlane¹, Morey Haymond², David Dunger³, Robert Chilton 2015 pending *Diabetes Care*

Ian J. Neeland MD,¹ Darren K. McGuire MD MHSc,^{1,2} Robert Chilton MD,³ Susanne Crowe,⁴ Søren S. Lund MD,⁴ Hans J. Woerle MD,⁴ Uli C. Broedl MD,⁴ and Odd Erik Johansen MD⁵ Effects of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin on Body Weight and Markers of Visceral Adiposity and Body Fat in 3,300 Patients with Type 2 Diabetes. Pending publication 2015

Thomas Jax , Robert Chilton, Nikolaus Marx. A Randomized, Active- and Placebo-Controlled, Three-Period Crossover Trial to Investigate Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Endothelial Function in Type 2 Diabetes. *American College of Cardiology* 2015;505:343

Chilton, Robert. Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists. *Diabetes and Metabolism* 2015;6:1

Rushit Kanakia, Shaun Martinho, Tejas Patel, Faisal A. Arain, Manoj M. Panday, Claude J. Le Saux, Son V. Pham, Steven R. Bailey, and Robert Chilton. Does dipeptidyl peptidase IV inhibitor increase the risk of heart failure? A cardiologist ' s paradox. *Cardiovascular Endocrinology* 2014, Vol 00 No 00

David A. Johnson, MD, MACG, FASGE, FACP; Robert Chilton, DO, FACC; Harley R. Liker, MD. Proton-Pump Inhibitors in Patients Requiring Antiplatelet Therapy. *Postgraduate Medicine.* Volume: 126 Number: 3 Month: May, 2014

Sethi S, Rivera O, Oliveros R and Chilton R. Aortic Stiffness: Pathophysiology, Clinical Implications and Approach to Treatment. *Integrated Blood Pressure Control* , IN PRESS 2014

Molina-Wilkins M, Chilton RJ, DeFronzo RA. Pioglitazone Improves Myocardial Glucose Uptake and Myocardial Blood Flow in Type 2 Diabetic Subjects. *Diabetes* 2012;61 (suppl 1):A237.

K. Y. DELEON, A. YABLUCHANSKIY, M. D. WINNIFORD, R. A. LANGE, R. J. CHILTON and M. L. LINDSEY. Modifying matrix remodeling to prevent heart failure. DOI: 10.1533/9780857096708.1.41 Book chapter 2014

Sanon V, Sanon S, Kanakia R, Yu H, Araj F, Oliveros R, Chilton R. Hypoglycemia from a Cardiologist's Perspective Clin Cardiol IN PRESS 2014 Jan

Yu-Fang Jin, Lindsey M, Lange R, Chilton R Integrative Computational and Experimental Approaches to Establish a Post-Myocardial Infarction Knowledge Map. PLOS Computational Biology, 2014

Dolores Cortez, Son Pham, Yu-Fang, Hiroe Toba, Merry L. Lindsey, Robert J. Chilton. The Elusive Vulnerable Plaque: Translational Biology Potential. Journal of Cardiology and Vascular Medicine 2013;1:e102

Andriy Yabluchanskiy, Robert J. Chilton, Merry L. Lindsey
Left Ventricular Remodeling: One Small Step for the Extracellular Matrix
Will Translate to a Giant Leap for the Myocardium. Congest Heart Fail. Aug 2013;19:E5–E8

Henry R, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus. Journal of Diabetes and Its Complications June 2013 XXx

Yonggang Ma, Andriy Yabluchanskiy, Merry L. Lindsey and Robert J. Chilton. Is Isolated Systolic Hypertension Worse than Combined Systolic/Diastolic Hypertension? Journal of Clinical Hypertension 2012;14:808-809.

Chilton R, Trading Glucose Control for Hypertension: Lessons from Mother Nature. Clinical Diabetes 2013;31:21-25

Pham S, Pham PT and Chilton R. Glycemic control in type 2 DM: The Tighter the Better? Clinical Diabetes 2013;31:26-28

Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vascular Health and Risk Management November 2012 Volume 2012:8 Pages 621 – 629.

Andriy Yabluchanskiy, YaoJun Li, Robert J. Chilton, and Merry L. Lindsey. Matrix metalloproteinases: drug targets in myocardial infarction. Current drug targets 2012 in press

Chiquette E, Toth P, Ramirez G, Cobble M, Chilton R. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vascular Health and Risk Management 2012:8:621-629

Suraj Maraj, Rikesh Patel , Rene Oliveros, Saurabh Sanon , Tim Dao , Sik Hur and Robert Chilton. Potential Cardiometabolic Benefits of Renal Artery Denervation in Diabetics. J Diabetes and Metabolism 2012, ISSN:2155-6156 JDM,S:3

Ma Y, Chilton RJ, Lindsey ML. Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension. 2012 May;59(5):908-10

Chilton R. IC bolus only versus IV with infusion 2b/3a inhibitors during STEMIs having PCI. *Catheter Cardiovasc Interv.* 2012 Jan 1;79(1):68-9

Sanon S, Patel R, Eshelbrenner C, Sanon VP, Alhaddad M, Oliveros R, Pham SV, Chilton R. Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist. *Am J Cardiol.* 2012 Nov 6;110(9 Suppl):13B-23B. doi: 10.1016/j.amjcard.2012.08.035

Suraj Maraj, Rikesh Patel, Saurabh Sanon, Tim Dao, Rene Oliveros, Robert Chilton. Potential Cardiometabolic Benefits of Renal Artery Denervation in Diabetics Published *Journal of Diabetes and Metabolism* 2012, S3:007. doi:10.4172/2155-6156.S3-007

Rikesh Patel, MD, and Robert J. Chilton, DO, FACC. Another Telescope for Examining Statins: the SATURN Trial. *Clinical Diabetes* July 1, 2012 vol. 30 no. 3 115-119

Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. *Cardiovasc Ther.* 2012 Jun;30(3):e146-55

Saurabh Sanon, MD*, Vani P. Sanon, MD** Margo Drennon, RN, BSN, CNOR and Robert Chilton DO, FACC, FAHA. ORIGIN: The devil is in the details. *Diabetes Vanguard* 2012; June 14, 2012

Yonggang Ma, Robert J. Chilton, Merry L. Lindsey. Heart Rate Reduction An Old and Novel Candidate Heart Failure Therapy. *Hypertension* May 2012

Carrie Eshelbrenner, MD, Karina Vasquez, MD, Liberty O Yanze, MD, FACC, Rene Oliveros, MD, FACC, FACP and Robert Chilton, DO, FACC, FACP The Cardiologist's Role in the Management of Type 2 Diabetes. *US Cardiology*, 2012;9(1):26-9

Nguyen Nguyen, Xiaolin Zhang, Yunji Wang, Galen Schmidt, Richard A. Lange, Robert J. Chilton, Hai-Chao Han, Merry Lindsey, and Yu-Fang Jin
TARGETING MYOCARDIAL INFARCTION-SPECIFIC PROTEIN INTERACTION NETWORK USING COMPUTATIONAL ANALYSES. Pending publication

Shailesh Nandish, J Wyatt, O Bailon, R Oliveros, Robert Chilton. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. *Am J Cardiol.* 2011 Aug 2;108(3 Suppl):42B-51B.

Laura Harmon, MS,¹ Robert J. Chilton, DO, FACC,² Craig Spellman, DO, PhD, FACOI³ Reducing Cardiovascular Events and End Organ Damage in Patients with Hypertension: New Considerations. *Post Graduate Medicine* 2011;123:7-17

Robert Chilton. Fluvastatin versus pravastatin The American Journal of Cardiology, Volume 78, Issue 1, 1 July 1996, Page 127

Shailesh Nandish, Oscar Bailon, Jamison Wyatt, John Smith, Adrienne Stevens, Mike Lujan, Robert Chilton. Vasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence? Current Atherosclerosis Reports (3 February 2011), pp. 1-6.

Robert Chilton, Jamison Wyatt, Shailesh Nandish, Rene Oliveros, Michael Lujan. Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide-1-Based Therapies. Am Journal of Medicine 2011;124:s35-s53

The Cardiovascular Effects of GLP-1 Receptor Agonists. Okerson T, Chilton RJ. Cardiovasc Ther. 2010 Dec 19.

G. Schernthaner & R. J. Chilton. Cardiovascular risk and thiazolidinediones—what do meta-analyses really tell us? Diabetes, Obesity and Metabolism 2010; 12: 1023–1035

Chilton R, Caribbean Cardiac Society Conference Express September 2010: "Real Current Therapeutic Challenge: From the Vulnerable Plaque Approach to Vulnerable Patient Management"

Jamison Wyatt, Shailesh Nandish, Rene Oliveros, Adrienne S. Zion, Michael S. Lujan, Robert Chilton. Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients. Vascular Health and Risk Management. June 2010.

Rene Oliveros, Michael Lujan, Robert Chilton. Hypertension and Cardiovascular Disease. Practical Diabetology. May 2010;29:11-15

Shailesh Nandish, Jamison Wyatt, Rene Oliveros, Adrienne Stevens Zion, Michael Lujan, Robert Chilton. A Cardiologist's View of Hypoglycemia. Current Atheroscler Rep 2010 March.

Nandish Thukral, Ed Bergen, Shailesh Nandis, Mike Lujan, Rene Oliveros, Robert Chilton. Cardioprotective Properties of GLP-1. Practical Diabetology. April 2010;29:13-18

Shailesh Nandish MD; Jamison Wyatt, MD; Nandish Thukral, MD; and Robert J. Chilton, DO. Evaluating the prevalence and progression of diabetes. JAOA 2010;110:e53-e56

Chilton R, Clinical implications of the metabolic syndrome. JAOA 2010;110:e51-e53

Chilton R, Attempting to Untie the Gordian Knock: Diabetes Patients with Cardiovascular Disease, Journal of Panhandle Health, Potter-Randall County Medical Society 2009; 19: 14-16

Zamilpa R, Chilton RJ, Lindsey ML. TNF alpha Converting Enzyme Roles in Hypertension-Induced Hypertrophy: Look Both Ways When Crossing the Street. Hypertension, in press 2009

Moore T, Whitte A, Chilton R, Silent Myocardial Ischemia: Diagnosis, Treatment and Prognosis. Consultant 2009;49:82-90.

Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R. GLP-1 Agonist-based Therapies: An Emerging New Class of Antidiabetic Drug With Potential Cardioprotective Effects. Current Atherosclerosis Reports 2009; 11:93-99.

Linn W, Chilton R. Pharmacotherapy for Primary Care Book Chapter 4 Arrhythmias, 2008. McGraw Hill Second Edition

Dipiro JT, Talbert RL Pharmacotherapy Textbook. Seventh Edition-2008, Cardiovascular Disorders. Chilton RJ, Talbert RL Cardiovascular Testing

D. John Betteridge, Ralph A. DeFronzo, and Robert J. Chilton. PROactive: time for a critical appraisal. European Heart Journal (2008) 29, 969–983

Hoeben BJ, Chilton RJ. *Peripheral Arterial Disease: Treatment Guidelines. Primary Care Quarterly.* 2008;12:31-39.

McFalls EO, Chilton RJ. *Clinical factors associated with long-term mortality following vascular surgery; Outcomes from The Coronary Artery Revascularization Prophylaxis (CARP) Trial.* *J. Vasc Surg.* 2007;46:694-700

Nissen S, and STRADIVARIUS Investigators. *Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease.* *JAMA* 2008;299:1547-1560.

Nissen S, and PERISCOPE Investigators. *Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes.* *JAMA* 2008;299:1561-1573.

Betteridge J, DeFronzo R, Chilton R. *PROactive: A Time for Critical Appraisal.* *European Heart Journal* 2008; April

Sulistio MS, Zion A, Thukral N, Chilton R. *PPAR gamma agonists and Coronary Atherosclerosis.* *Current Atherosclerosis Reports* 2008;10:134-141

Chilton RJ. *Treating dyslipidemia in diabetes and metabolic syndrome.* *AOA Health Watch.* Volume 2. Number 3 November 2007.

Sulistio, Melanie, Lujan, M, Chilton, R. *New Strategies for Treating Atherosclerosis.* *Cardiology Quarterly,* Vol 1, 2007.

Sulistio, Melanie, Ramavathi Nandyala, Michael Lujan, Adrienne S. Zion, Robert Chilton. *Interventional Cardiology and the Patient with Type 2 Diabetes.* *Practical Diabetology* Vol 26 Number 3 September 2007, 6-14.

Chilton, RJ *Diabetes and Future CV Risk.* *NPAM AHA Council Connections* 2007 Vol 5, No 1, 29-30

Beaudry, D, Stone, KE, Wetherold, S, Hemphill, John, Do, D, McClish, J, Chilton, R: *Statin Therapy in Cardiovascular Diseases Other Than Current Atherosclerosis.* *Jan* 2007;9:25-32

Stone, KE, Chiquette, E., Chilton, R. *Diabetic Endovascular Disease: Role of Coronary Artery Revascularization.* *American Journal of Cardiology* February 19, 2007;99:105B-112B

Alvarez, JA, Chilton, R. *Thiazolidinediones: Effects on Cardiovascular Disease in Diabetes Patients.* *Primary Care Quarterly* September 2006;Vol 1:49-56.

Ward, HB, Kelley, RF, McFalls, others *Edward Coronary Artery Bypass Grafting is Superior to PCI in prevention of Perioperative MIs During Subsequent Vascular Surgery.* *Ann Thorac Surg* 2006;82:795-801

R.J. Chilton, B. Riggs. *Response Rates of the Highly Cardioselective β_1 -adrenergic Receptor Blocker Nebivolol in Mild-to-Moderate Hypertension.* *JAOA* • Vol 106 • No 8 • August 2006 • 488-489

Giles, TD; Chaitman, BR; Chilton, R; Kannel, WB; O'Rourke, R; Sander, GE; Sica, D. *Noval Approaches to the Treatment of Angina.* *LSU* April 2006.

Janet Hays, Michael Lujan, Robert Chilton. *Aortic Stenosis Catheterization Revisited: A Long Sheath Single- Puncture Technique.* *J INVASIVE CARDIOL* June 2006;18:262-267.

Dat DO, Jorge Alvarez, Elaine Chiquette, Robert Chilton. The Good Fat Hormone : Adiponectin and Cardiovascular Disease. *Current Atherosclerosis Reports* Volume 8 Number 2 March 2006:94-100

Chilton RJ, Dat Do, Meeney Dhir, Hikhil S Joshi, Ed Sako, Umesh K. Arora: Antiplatelet Therapy vs Warfarin for Prevention of Cerebrovascular Accidents after Bioprosthetic Valve Replacement or Repair. *Circulation* Oct 25, 2005;112:II-711

Chilton RJ, Egan BM, Basile J, Cohen JD. Cardioprotection: The Role of beta-Blocker Therapy. *J Clin Hypertens (Greenwich)*. 2005 Jul;7(7):409-16.

Chilton RJ, Stanislaw Skaluba, Steven Bailey, Devang Patel, Marc Feldman. Pretreatment with Statins Reduces Ischemic Neurological Events in Patients Undergoing Carotid Stent Implantation. *JACC* Feb 1, 2005;45:89

Chilton R, and Jorge Alvarez. Thiazolidinediones: Effects on Cardiovascular Disease in Diabetes Patients. *Cardiology Special Edition*. 2005; Volume 11:50-56

Chilton R, Chiquette E. Thiazolidinediones and cardiovascular disease. *Curr Atheroscler Rep*. 2005 Mar;7(2):115-20.

Chilton R. Web Alert: Focus: Diabetes and CV Disease *Curr Atheroscler Rep*. 2005 Volume 7 Issue 3: 3

Edward O. McFalls, M.D., Ph.D., Herbert B. Ward, M.D., Ph.D., Thomas E. Moritz, M.S., Steven Goldman, M.D., William C. Krupski, M.D.,* Fred Littooy, M.D., Gordon Pierpont, M.D., Steve Santilli, M.D., Joseph Rapp, M.D., Brack Hattler, M.D., Kendrick Shunk, M.D., Ph.D., Connie Jaenicke, R.N., B.S.N., Lizy Thottapurathu, M.S., Nancy Ellis, M.S., Domenic J. Reda, Ph.D., William G. Henderson, Ph.D and R Chilton. Coronary-Artery Revascularization before Elective Major Vascular Surgery. *N Engl J Med* 2004;351:2795-804.

Chilton R. Web Alert: Focus: Diabetes and National Guidelines *Curr Atheroscler Rep*. 2005 Volume 7 Issue 2: 4

Chilton R. Web Alert: Focus: Dietary Guidelines & Obesity *Curr Atheroscler Rep*. May 2005 Volume 7 Issue 1: 6

Chilton R. Web Alert: Focus: Diabetes and CV Disease *Curr Atheroscler Rep*. 2005 Volume 7 Issue 3: 3

Chilton R, Coadministration therapy in hypercholesterolemia: a novel approach to achieving lipid goals *J Am Osteopath Assoc*. 2004 Sep;104(9 Suppl 7):S3-4

R Chilton. National Lipid Education Council: PPAR Agonist: Not just for Patients with Diabetes? *NLEC* Volume 8 Number 4 2004

Chilton R, Pathophysiology of coronary heart disease: a brief review. *J Am Osteopath Assoc*. 2004 Sep;104(9 Suppl 7):S5-8

Chilton R. Web Alert: Focus: Free Online Publications for Physicians. *Curr Atheroscler Rep*. 2004 Volume 6 Issue 1: 5

Chilton RJ, Liberty Yaneza, Edmund Kerut, F. Dwight Chrisman, Thomas D Giles, Michael Lujan, Swangjit Suramornkul, Vivek J Goswami, Rosario Mercado-Young, Carlos Alviar, Shuko Lee, Robert O'Rourke. Association of Lipoproteins with Different Plaque Compositions as Evaluated by Intravascular Ultrasound JACC March 19, 2004;43, Issue 5: March 3, 2004, page 34

Chilton RJ. Type 2 Diabetes, Cardiovascular Risk, and the Link to Insulin Resistance Clinical Therapeutics 2003;2:1-6

Chilton R, Chiquette E, Is the use of unfractionated heparin in acute coronary syndrome outmoded? Curr Atheroscler Rep. 2004 Mar;6(2):94-100.

Chilton RJ, and B. Egan. The Role of B-Blockers in the Practical Management of Hypertension Post Graduate Medicine 2003 Dec: 25-46.

Chilton R, Stolar MW. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther. 2003;25 Suppl B:B4-3

Chilton RJ. Web Alert. Focus Diabetes & CV Disease Curr Atheroscler Rep 2003 Jul;1(1):3-3.

Chilton RJ. Lipid and nonlipid benefits of statins J Am Osteopath Assoc 2003 Jul;103(7sup3):S12

Chilton Robert, Rosario A. Mercado-Young, Liberty O. Yaneza, Swangjit Suraamornkul, Judith J. Nicastro, Shuko Lee and Robert A. O'Rourke Safety, efficacy, and effect on glucose levels of once-daily niacin on patients with Dyslipidemia Journal of the American College of Cardiology, Volume 41, Issue 6, 19 March 2003, Page 245

Chilton RJ, E Chiquette. Aggressive medical management of coronary artery disease versus mechanical revascularization Curr Atheroscler Rep 2003 Mar;5(2):118-123.

Chilton R, Chiquette E. Cardiovascular disease: much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep. 2002 Mar;4(2):134-42

Chilton RJ. The new "lower is better" lipid goals: are they achievable with today's drugs? J Am Osteopath Assoc. 2002 May;102(5 Suppl 1):S1-5

Chilton RJ, Clearfield M, Carr Larry. The Cholesterol Challenge: Navigating the Adult Treatment Panel III Guidelines JAOA Supplement 1 2002 May;102(5)

Chilton RJ. Cardiovascular Disease: much more aggressive in patients with type 2 diabetes Curr Atheroscler Rep 2002 Mar;4(2):134-142.

Chilton RJ. Web alert. Focus: Online Textbooks of Medicine Curr Atheroscler Rep. 2001 Jan;3(1):3

Chilton R, O'Rourke RA. The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease. Curr Probl Cardiol. 2001 Dec;26(12):734-64.

Chilton R. Pharmacologic Websites for Physicians. *Curr Atheroscler Rep.* 2001 Jul;3(4):271-2

Chilton RJ. Recent discoveries in assessment of coronary heart disease: impact of vascular mechanisms on development of atherosclerosis.
J Am Osteopath Assoc. 2001 Sep;101(9 Suppl):S1-5

Chilton RJ. Web alert. Clinical websites for Cardiologist. *Curr Atheroscler Rep.* 2000 Jan;2(1):5-6

Chilton RJ. Web alert. Interventional Cardiology Websites *Curr Atheroscler Rep.* 2000 Jul;2(4):275

Chilton RJ. Web alert. Patient Information websites for teaching. *Curr Atheroscler Rep.* 2000 Sep;2(5):355

Chilton RJ, Kiesz RS, Rozek MM, Ebersole DG, Mego DM, and Chang CW Novel approach to rotational atherectomy results in low restenosis rates in long, calcified lesions: long-term results of the San Antonio Rotablator Study (SARS).
Catheter Cardiovasc Interv. 1999 Sep;48(1):48-53

Chilton RJ. Web alert. Websites for clinical trials. *Curr Atheroscler Rep.* 1999 Sep;1(2):133

Chilton RJ, Kiesz RS, Rozek MM, Mego Dm, Nader JA, O'Leary E, Patel V, Saunders-Webb E, and Ebersole DG. Acute Directional Coronary Atherectomy Prior To Stenting Decreases Restenosis in High Risk Lesions JACC 1998;31(5):451

Chilton RJ, Do D, Marcus R, Froelicher V, Janosi A, West J, Atwood JE, Myers J, and Froning J. Predicting severe angiographic coronary artery disease using computerization of clinical and exercise test data. *Chest.* 1998 Nov;114(5):1437-45

Chilton R, Kiesz RS, SR Bailey, MM Rozek D Mego, E o'Leary, M Wood, D Sorenson, and L Miller. High Speed Rotational Atherectomy Combined with Low Pressure Balloom Angioplasty Reduces Residual Stenosis JACC 1998

Chilton RJ, Kiesz RS, Rozek MM, Mego DM, Patel V, and Ebersole DG Acute directional coronary atherectomy prior to stenting in complex coronary lesions: ADAPTS Study.
Cathet Cardiovasc Diagn. 1998 Oct;45(2):105-12.

Chilton R, Atwood JE, Do D, Froelicher V, Dennis C, Froning J, Janosi A, Mortara D, Myers J. Can computerization of the exercise test replace the cardiologist?
Am Heart J. 1998 Sep;136(3):543-52.

Chilton R, Bailey SR, and O'Leary E. Angioscopic evaluation of site-specific administration of ReoPro.
Cathet Cardiovasc Diagn. 1997 Oct;42(2):181-4.

Chilton RJ Fluvastatin versus pravastatin.
Am J Cardiol. 1996 Jul 1;78(1):127

Chilton R, Kiesz RS, Rozek MM, Mego DM, Miller L, O'Leary E, Bailey RS, Saunders-Webb E, and Ebersole DG. Device Synergy: Directional Atherectomy and Stenting Significantly Decreases Residual Stenosis Eur H Journal 1996;17(175)

Chilton R, Kiesz RS, TOole II, TC, Palmaz J, Defalco A, Rozek MM, and Bailey SR. Directional Coronary Atherectomy Combined with Palmaz-Schatz Stent Placement Eliminates Residual Stenosis J Invasive Cardiol 1995;7(1):10-15

Chilton RJ, Jain A, O'Rourke RA. Mechanism of "reciprocal changes: during acute ischemia Circulation 1993;1635

Chilton R, Taylor RL, Cohen DJ, Widman LE, and O'Rourke RA. Infection of an implantable cardioverter defibrillator: management without removal of the device in selected cases. Pacing Clin Electrophysiol. 1990 Nov;13(11 Pt 1):1352-5

Chilton RJ. Introduction to the symposium on practical aspects of angiotensin-converting enzyme inhibition. J Am Osteopath Assoc. 1987 Feb;87(2 Suppl):164-5

Chilton RJ. Practical Aspects of angiotensin-converting enzyme inhibition. J Am Osteopath Assoc 1987;2 Sup:164-165.

Chilton RJ, Oliveros RA, Kruyer WB, Beckmann CH, Boran KJ. Unusual response to intravenous verapamil in a patient with atrial fibrillation. South Med J. 1982 Nov;75(11):1429-30.

Chilton RJ. Twenty-three years of addict reporting: a reanalysis of police supplied drug use data J Psychoactive Drugs 1981;13(3):266

Chilton RJ, Curry CL. Outpatient cardiac rehabilitation: a discription of the program at Wilford Hall USAF Medical Center Milit Med 1981;146(4):241-242.

Chilton RJ, Jacobs RL, Rake GW Jr., Fournier DC, Culver WG, Beckman CH. Potentiated anaphylaxis in patients with drug- induced beta-adrenergic blockade J Allergy Clin Immunol 1981;68(2):125-127.

Chilton R. Twenty-three years of addict reporting: a reanalysis of police supplied drug use data. J Psychoactive Drugs. 1981 Jul-Sep;13(3):255-66

Chilton RJ, Oliveros RA, Beckman CH. Emergency room recognition and management of cardiac arrhythmias South Med J 1981;74(12):1546-1547.

Chilton R, Miller RI, Johnson RP, Ryan DE. Cardiopulmonary resuscitation: a teaching aid. J Oral Surg. 1980 Jul;38(7):513-5

Chilton RJ, Oliveros RA, Stutts BS, Beckman CH. Echocardiographic systolic time intervals. Left ventricular performance in coronary artery disease Arch Intern Med 1980;140(2):240-243.

Chilton R, Oliveros RA, Boucher C, Ellis B, and Butcher E. Usefulness of systolic time intervals by echocardiography in assessment left ventricular performance in coronary artery disease Chest 1978;74(3):346

PRESENTATIONS:

European Society of Cardiology Paris 2019: **Relationship between hypoglycemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial**

ADA meeting: Opening address 2018: The Failing Heart

China Cardiometabolic summit: 2018: Slowing down accelerated progression of Cardio-renal disease in t2dm

Taiwan University Endocrine Grand Rounds 2018: Current status on Management of calorie intoxication: interventional cardiology perspective

International Asia Conference on Diabetes 2018: Tackling the unmet needs of Type 2 Diabetes Mellitus comorbidities

Regional Meeting: 2018 3rd Annual Diabetes, Obesity and Metabolic Disease Conference
Session: Preventing Vascular Disease in the High-Risk Cardio-Metabolic Patient : Preventing Vascular Disease in the High-Risk Cardio-Metabolic Patient

National ACOI cardiology meeting 2018: Goal-Directed Therapy in Lipid Management

Mexico City National Endocrine meeting 2017: PPAR and the Heart 2017

ISN World Congress of Nephrology (*WCN*) in *Mexico City* from April 21 to 25, 2017

SEMDSA (Society for Endocrinology, Metabolism and Diabetes of South Africa) Scientific sessions-2017: Mechanism of action: SGLT2 inhibitors and other lectures

National endocrine society 2017: Thailand

ADA_48th_annual_meeting_ Effects of Empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-REG OUTCOME®

ADA 47th annual meeting: Chairman for Tissue lipids and lipoproteins 2016

Ischemia Trial: whats new? The 47th Annual Convention and Scientific Meeting Philippine Heart Association 2016

Handling complex bleeding complications in cath lab: Annual Convention Philippine Collage of Cardiology May 2016

EMPA-REG OUTCOME: A cardiology perspective of Diabetes and CV disease. The 47th Annual Convention and Scientific Meeting Philippine Heart Association 2016

The management of Type 2 Diabetes Mellitus: CV Outcomes Studies (EXAMINE & SAVOR & TECOS) of DPP4i 2016 TSOC & Cardiovascular & Metabolism (CVM) China

Translational effects of new RAAS blockers with insulin sensitization. 46th Annual Convention & Scientific Sessions of the Taiwan Society of Cardiology 2016.

ASH/ISH guidelines for HT: EAST meets West. 46th Annual Convention & Scientific Sessions of the Taiwan Society of Cardiology 2016.

Treatment and prevention of diastolic dysfunction in diabetes. International Cardio-metabolic convention. Dubai 2016

Incretin effects on the insulin resistant heart. 48th Annual India CV meeting. 2016

Role of SGLT2 inhibitors in reducing cardiovascular death and heart failure in diabetes. Scientific session at 11th Intl Healthy Aging Symposium 2016 Hong Kong

Role of biomarkers in CV disease in insulin resistant patients. Sociedade Brasileira de Diabetes 2016, Rio

Mexican Society of Nutrition and Endocrinology: Cardiovascular evaluation of outcome trials with DPPIV inhibitors 2015

13 World Congress on Insulin Resistance: Lipodystrophic Heart: More Than Fatty Heart Disease

13 World Congress on insulin Resistance Diabetes and CV disease: The Cardiologist Perspective: Impact of Low LDL on IVUS

ADA 2015: Clinical considerations in patients with CV disease after ELIXER and TECOS

Annual European Heart Failure meeting-Seville 2015. Invited presentation :Heart failure and the Renin-Angiotensin System: translational perspective

Annual European Heart Failure meeting-Seville 2015. Invited presentation: Treatment of Diabetes Patients with HT and Heart Failure

The sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type 2 diabetes 2015 ESH

Empagliflozin Reduces Systolic Blood Pressure in Dipper and Non-Dipper Patients with Type 2 Diabetes and Hypertension. European Society of HT June 2015

6th CV Metabolic symposium Dubai 2015. Evolving trends in dyslipidemia: translational view of of current clinical research.

New Era of Lipid and Glycomedicine Research. Kaohsiung Medical School. 2015

ESC HF conference

17 th Advanced Course on the Treatment of Diabetes: The Newest DPP-4 Inhibitor and Insights Into Recent Cardio Vascular Outcomes Data 2015 Brazil Sao Paulo

International Cardiometabolic meeting: Tbilisi Russia 2015 : PPARs Current CV considerations

International Cardiometabolic meeting: Tbilisi Russia: Heart failure concerns and Incretins

EASD Sept 2014 Vienna Austria: CV safety of Diabetes Medication: Where are we going?

12th World Congress on Insulin resistance: Peripheral arterial disease and disease

12th World Congress on Insulin resistance: Diabetes: A look inside from new imaging research

XXXVII Congress National de Medicina Interna 2014 State of the art: CV effects of antidiabetes drugs

Latin America Annual Cardiometabolic symposium 2014: Cardiovascular Implications of New Diabetes Trials

28th Annual Cardiology Summit Barnes-Jewish St. Peters Hospital, St Louis Missouri, Key note address: Changing landscape of Incretins in Cardiovascular Disease April 2014

Annual National Society of Endocrinology and Nutrition Dominican Republic 2014: DPP 4 inhibitors and the CV system: Potential concerns

International Web-teleconference Lebanon National Endocrinology Meeting 2014: Role of Incretins in Cardiometabolic disease.

ACC 2014: Role of 5HT-2b Therapy in CV disease

Annual International Cardiometabolic Summit, Kobe University, Japan 2014

International diabetes federation meeting Melbourne IDF 2013

Invited presentation: Translational biology of hypertension in type 2 diabetes

Invited presentation IDF 2013: CV implications of PPARs in type 2 diabetes: a look from IVUS

Invited presentation IDF 2013: DPP 4 inhibitors and translational consideration in heart failure

Invited presentation: National AOA meeting October 2013: Translational biology of acute coronary syndrome

Invited presentation: 9th National Cardiometabolic Congress: New dimensions of GLP-1 agonist in the heart of diabetes.

Invited presentation: 9th National Cardiometabolic Congress: Translational effects of obesity and atherosclerosis.

Invited presentation: Asian International Diabetes Conference South Korea 2013
Role of Incretins in CV Disease: Focus DPP 4 inhibition

Invited presentation European Society of Cardiology 2013
Incretin treatment in type 2 diabetes: SAVOR and EXAMINE CV implications

Invited presentation European Society of Cardiology 2013
Potential of miRNA in Cardiovascular Disease

Invited presentation: Annual Asian Cardiometabolic Summit: Istanbul Turkey 2013:
Cardiovascular continuum: Incretins

Invited presentation for Philippines Lipid and Atherosclerosis Society: HDL 2013 symposium, the role of remnant cholesterol and HDL

Presentation for Philippine Society of Hypertension 2013 Annual meeting: Pharmacotherapy for Hypertension: New Trend in Getting Patients to BP Goal

International Congress on HT, Spain 2013: CV implications of microRNA

11th Annual World Congress on Insulin Resistance 2012; Energy Starved Heart in Diabetes

National 2012 ACOI meeting: Cardiovascular Implications of New Antithrombotics

Cardiometabolic Health Congress (CMHC) 2012: Cardiovascular effects of GLP-1

APSAVD 2012 National Cardiology Annual Meeting: Genetic and molecular basis of atherosclerosis

14th Cardiovascular Summit China: Vascular Effects of PPARs in Cardiovascular Disease 2012

National Lipid Association 2012 Scientific Sessions: Reduction in Estimated 10 year Coronary Heart Disease Risk using Reynolds Risk Score: A Post HOC analysis of Exenatide-Treated patients with type 2 diabetes: Elaine Chiquette, Gilbert Ramirez, Peter P. Toth, Michael Cobble, Robert Chilton

National Lipid Association 2012 Scientific Sessions: Treatment With Exenatide BID and QW for 30 Weeks was Associated With Favorable Lipid and Lipid Subclass Changes in Patients With Abnormal Baseline Values. Peter P. Toth, Robert Chilton, Gilbert Ramirez, Michael Cobble, Elaine Chiquette

26 Annual Indonesian Medical Association Scientific Sessions 2012: Current and Future Cardiovascular Disease Management

South American Congress of Cardiology 2012: Cardiovascular Risk Management in 2012: what to expect

World Congress of Cardiology, Dubai 2012 Scientific Sessions: Long term CV outcomes involving RAAS

World Congress of Cardiology, Dubai 2012 Scientific Sessions: Treatment of Hypertension: sympathetic blockade

National Lipid Association 2012 Annual Scientific Sessions: Targeting adiposopathy in the treatment of metabolic syndrome

Presented at the Obesity Society's 29th Annual Scientific Meeting, October 1-5 2011, in Orlando, F: Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart Failure

Sept 2011, Presentation at EASD: Treatment with Exenatide BID and QW for 30 Weeks Was Associated With Favorable Lipid Subclass Changes

August 2011, Invited presentation American Association of Clinical Endocrinologists. Opening address: GLP-1 and CV disease: A look ahead

July 2011, Invited presentation at National Cardiology meeting in Jakarta. Metabolic vs environmental treatment in Cardiovascular Disease prevention

June 2011, Invited presentation Shanghai China Department of Medicine Lecture: Evolving Role of Pharmacotherapy in Vascular Hypertrophy

June 2011, Invited presentation 45th CV symposium Hong Kong - Global Risk Reduction: Lessons from COURAGE

WORLD CONGRESS OF CARDIOLOGY SCIENTIFIC SESSIONS 2010: 16–19 JUNE, BEIJING, China
Presentation CV role of PPARs: Focus on IVUS, second invited talk: Antiplatelets vs statins reducing CV events

May 2010 Invited presentation Singapore 10th Annual National CV Convention. Role of pharmacotherapy in reducing atherothrombotic events.

September 2010: Fiesta Cardiology University of Texas Health Science Center: P2Y12

August 2010, Invited presentation at East Meets West in Cardiology, 2010 Bangkok Thailand.
Metabolomics and Global Risk Reduction: Insulin resistance

August 2010: American Association of Diabetes Educators 37th National Meeting: Lecture Diabetes is Heart Disease

August 6, 2010: AADE National meeting: Lecture: Beyond Glucose Control the Vascular Bed

August 5, 2010: AADE National Meeting: Lecture: Clinical Trials in Type 2 Diabetes: Macrovascular Events

June 2010: Invited Speaker 70TH American Diabetes Meeting: Diabetes Close to the Heart

June 2010: Invited speaker: 25th National Caribbean Cardiology Conference
Current Therapeutic Challenge: Vulnerable Patient Traditional Risk Factors to Genomics

June 2010: Invited speaker: World Congress of Cardiology, China
PPARs and Cardiovascular System

June 2010: Invited speaker: World Congress of Cardiology, China
Diabetes and Cardiovascular Disease: Role of Current Therapies

June 2010: Indonesia Cardiology Society Symposium: Role of TZD in Vascular Bed

June 2010: Invited speaker: Hong Kong Cardiology Society: Role of ARBs in Diabetic CV Disease

May 2010: Invited speaker: 50th Annual Convention and Scientific Sessions Taiwan Society of Cardiology
Insulin Resistance Impact in Cardiovascular Metabolic Toxicity

April 10: Pathobiology and Treatment of the Vulnerable Patient: National Society of Panama

April 10: Global Risk Reduction in the 21st Century: Annual Dominican Republic Cardiology Meeting

April 10: The Vulnerable Patient: Treatment Considerations: National Costa Rica Cardiology Meeting 2010

Dec 09: New Trends in Cardiovascular Treatment: Targeting the High Risk Patient – Pasay City, Asia

Nov 09: National Endocrinology Meeting in China

Aug 09: India: Cardiology Meeting in Hyderabad

Aug 09: India: Endocrinology Meeting in Mumbai

- July 09: Vascular Biology Working Group Asian Meeting: The Vulnerable Plaque as a Target for lipid management
- July 09: Vascular Biology Working Group Asian Meeting: Lipid Management: combining statins and fibrates, what are the issues
- July 08: Masters in Lipidology Course Lecture: Pathogenesis of Atherosclerosis
- July 08: National Lipid Association National Meeting: Imaging as a Biomarker: Will it Change Patient Care?
- July 08: Singapore 7 Country Asian Summit: Macrovascular Disease in Type 2 DM: Inside look at the coronary vasculature (PERISCOPE and Stradivarius)
- July 08: National Malaysian Endocrine and Metabolic Sessions: Can We Slow the Progression of Macrovascular Disease in Type 2 Diabetes?
- June 08 ADA National meeting invited lecture: IVUS & Cardiovascular Effects of Obesity and Diabetes
- May 08 Ventricular Ectopy and Ventricular Tachycardia- Can it be Cured. Lehigh Valley Medical Center
- Apr 08 International Symposium on Heart Failure Mumbai India: Tissue Engineering "Future Considerations"
- Mar 08 American College of Cardiology: PERISCOPE "Clinical Implications of Surrogate Endpoints"
- Sept 07 European Association for the Study of Diabetes. Invited Speaker: Cardiac Lipotoxicity
- Nov 05 Translational Biology of Heart Failure. ACP Army National Meeting, San Antonio, Texas
- Oct 05 Thomas Jefferson University Cardiology Grand Rounds: Diabetes and CV Disease Evolving Science
- Oct 05 Temple University Grand Rounds:PPARs and CV Disease
- 8/2005 Pharmacogenomics and Cardiovascular Disease. Grand Rounds University of Oklahoma Cardiology Division. Invited
- 7/2005 Region 6 Malaysia Society Meeting: CME: HDL and Treatment of Cardiovascular Disease- CME Invited
- 7/2005 Malaysian Cardiovascular Society: CME: Vascular Biology in 21st Century Clinical Considerations: Focus Diabetes Kuala Lumpur, Malaysia Invited
- 7/2005 National Vascular Biology Faculty Advisory Board Meeting: Focus Diabetes: Clinical Endpoints Trials and Cardiovascular Disease CME invited
- 7/2005 2005 Malaysian CV Interventional Symposium with Live Transmission Kuala Lumpur: Anti Atherosclerosis-Is it the next Big Thing? Invited

- 5/2005 Medicine Grand Rounds Oschner Clinic: CME: Cardiovascular Disease 21st Century: Focus Diabetes and Vascular Biology Invited
- 5/2005 Cardiology Grand Rounds Oschner Clinic: Cardiometabolism: Inside Look into the Future of Cardiology Invited
- 5/2005 Hawaiian Cardiovascular Summit: Beyond LDL reduction – HDL & PPARs Invited CME
- 5/2005 8th Annual Asian Pacific Cardiology Symposium: Is Human Regression of Atherosclerosis Possible? Shanghai, China CME invited
- 5/2005 Queen Hospital Medical Grand Rounds: Heart Failure: Drugs & Devices: Focus Heart Failure
- 4/2005 SAN SALVADOR Cardiovascular Symposium: Global Risk Reduction: Beyond the Numbers Invited
- 4/2005 PANAMA CITY Cardiovascular Symposium: Multiple Risk Factor Intervention: Does it Work? CME invited
- 4/2005 GUATEMALA Cardiovascular Symposium: Targeting Total CV Risk: Benefits of Global Cardiovascular Risk Reduction CME invited
- 4/2005 TEGUCIGALPA Cardiovascular Symposium: Benefits of Global Cardiovascular Risk Reduction vs Interventional Procedures –Shared Benefits CME invited
- 3/2005 Capetown South Africa: 34th Annual CV Summit: Role of Endothelium in Health and Disease Invited
- 3/2005 Joberg South Africa: New Directions in Cardiovascular Treatment: Beyond LDL reduction Grand Rounds CME invited
- 3/2005 Free State South Africa: Diabetes and CV Disease: New Treatment Directions CME invited
- 3/2005 Durban South Africa 56th Annual Cardiovascular Symposium: Role of Global Risk Reduction in Vascular Health CME invited
- 12/2004 Cardiology Grand Rounds- Baylor Medical School: Multiple Risk and Cardiovascular Prevention
- 11/2004 Hypertensive Cardiovascular Disease "Focus on Clinical Vascular Biology", New Delhi: Medical Center Grand Rounds, New Delhi (India)
- 11/2004 Role of Cardiovascular Drugs in Plaque Stabilization, National Cardiology Meeting, National Cardiology Meeting, Hyderabad, India, Hyderabad, IN (India)
- 11/2004 Metabolic Syndrome and Cardiovascular Event: A New Target, American Heart Association Symposium, American Heart Association (New Orleans, LA)

- 11/2004 Lecture-Glitazones and Vascular Bed: Clinical Implications, 3rd Annual Cardiology Fellows Forum of Excellence AHA, AHA (New Orleans, LA)
- 11/2004 Role of Beta Blockers in Cardiovascular Protection, Boston Primed Meeting, Boston Primed Meeting (Boston)
- 11/2004 New Agents in the Treatment of Hypertension: Reaching the New Targets, Chairman for Regional Hypertension Symposium, Chairman for Regional American Society of Hypertension Symposium, San Antonio, TX
- 9/2004 Frankfurt Germany-9th Annual International Stroke & CV Symposium CME invited
- 9/2004 Costa Rica Cardiology-National Endocrine Society Meeting: Global Risk Management in 21st Century CME invited
- 9/2004 Endocrine Grand Rounds-Southwestern Medical School; Role of Cardiovascular Disease in the Diabetic Patient Invited
- 08/2004 Beyond Sugar with PPARs Opening address, Pennsylvania State Medical Association Meeting, Philadelphia, PA Invited CME
- 07/2004 The Vascular Wall and Cardiovascular Diseases University of Alabama, Internal Medicine Grand Rounds, AL CME Invited
- 07/2004 A Look Inside Diabetic Coronary Arteries, Cardiology Grand Rounds, University of Alabama, AL Invited CME
- 07/2004 Management of the Intermediate Risk Patient, Vascular Biology Working Group Symposium, Focus Global Risk Reduction CME invited
- 07/2004 Recent Clinical Lipid Trail Update, Regional Lipid Meeting, Focus on Diseases New Orleans, New Orleans, LA (Invited Speaker) CME
- 06/2004 Benefits of Global Risk Reduction in CV Disease Events, Texas Medical Association, Texas Medical Association (Invited Speaker) CME
- 06/2004 Cardiology 2004 : Preparing for the Examination, ABIM Board Review, American College of Physicians CME invited
- 06/2004 Metabolic Syndrome: Evaluation and Management of Cardiovascular Resk Factors, National Physicians Assistance Annual Meeting (Invited Speaker)
- 06/2004 Diabetes and CV Disease, UCLA Grand Rounds, UCLA (Invited Speaker-CME)

- 05/2004 Advancing Role of PPAR in Cardiovascular Disease, Heart Association Meeting, Heart Association, Lima, Peru (Invited Speaker)
- 05/2004 Global Risk Reduction and Impact on Cardiovascular Events, Lima Heart Association Meeting, Lima Heart Association, Lima, Peru (Invited Speaker)
- 05/2004 Evolving Role of PPARs in Cardiovascular Disease, Grand Rounds, Scripps Institute, San Diego, CA (Invited Speaker) CME
- 05/2004 Diabetes and CV Disease: IVUS and PPARs, Cardiology Grand Rounds, Baylor University, TX CME invited
- 05/2004 Glitazone and The Heart, Cardiology Grand Rounds Tulane University, Tulane University Invited CME
- 05/2004 How low should the Cholesterol go Go, Grand Rounds 6th Maui International Lipid Symposium, CV Disease 21st Century Maui Hawaii CME invited
- 04/2004 Beyond Glucose: Cardiovascular Risk and Treatment, 14th Annual Family Practice Meeting, University of Ohio School of Medicine, OH Invited CME
- 04/2004 Acute Coronary Syndrome and Statins Where do we go from Here?, NY National Lipid Summit NY, New York CME invited
- 04/2004 Diabetes and CV Disease, Endocrine Grands Rounds ULCA, LA, California CME invited
- 03/2004 Atrial Fibrillation Evolving Role of Catheter Ablation, Invitation to the Instituto Nacional de Cardiologia, Invitation to the Instituto Nacional de Cardiologia, Mexico City, MX CME invited
- 03/2004 Global Risk Reduction & Vascular Events, Hawaii University Grand Rounds, Hawaii University, Oahu, HI CME invited
- 03/2004 Acute Coronary Syndrome and Treatment Options, UTHSCSA Annual Family Practice Symposium, UTHSCSA, San Antonio, TX CME invited
- 03/2004 Vascular Wall Risk Factors: Focus on Diabetes, Medicine Grand Rounds @ North Texas State University, North Texas State University, TX CME invited
- 03/2004 Diabetes a Look inside at the Coronary vasculature with IVUS, National Diabetes Summit, National Diabetes Summit, Santa Monica, CA CME invited
- 02/2004 Carotid Stenting and Complications, International Stroke Prevention Symposium, Interventional Cardiology and Stroke Prevention, Ixpata,, MX CME invited

- 02/2004 Role of Gene Therapy & Cardiovascular Disease, Grand Rounds Texas Tech University, Texas Tech University, Lubbock, TX CME invited
- 02/2004 The Evolving Role of Beta Blockers in Heart Failure, Vascular Biology Working Group Regional Symposium CME invited
- 02/2004 Myocardial Regeneration, AHA Cardiovascular Nursing Task Force, AHA CME invited
- 01/2004 Role of Glitazones in Cardiovascular Disease, Annual Ohio University Diabetes Symposium, Ohio University, OH CME invited
- 01/2004 Global Risk Reduction & Clinical Vascular Biology, Wilford Hall USAF Medical Center, Wilford hall USAF Medical Center, San Antonio, TX CME invited
- 01/2004 Angiogenesis Clinical Implications, 34 Annual Nevada State Internal Medicine Meeting, Nevada State, NE CME invited
- 01/2004 Emerging Role of PPARs in CV Disease, Grand Rounds Tulane University, Tulane University CME invited
- 01/2004 Global Risk Reduction and CV Disease, 38th Annual ASHP meeting, ASHP San Antonio, Texas CME invited
- 12/2003 Post Intervention Continuum of care: Focus on Lipid management in acute and long term setting, Memorial Health University Medical Center, Memorial Health University Medical Center CME invited
- 11/2003 Vascular Biology and Clinical Considerations for Gene Therapy, 45 Annual Cardiology Symposium, 45 Annual Cardiology Symposium, Mumbai, India CME invited
- 10/2003 Emerging Role of PPARs in Cardiology, National Diabetes Symposium, National Diabetes Symposium San Diego California CME invited CME
- 10/2003 Changing Roles in the Treatment of Heart Failure, Primed Symposium, Primed Symposium, Washington DC, WA invited CME
- 10/2003 Is Lower Cholesterol Better?, 56 Annual AOA Meeting, AOA Montréal Canada CME invited
- 10/2003 Acute Coronary Syndrome, Current Treatment Considerations, Washington University School of Medicine-ACP, Washington University School of Medicine-ACP
- 10/2003 Stroke Prevention: Statins more than LDL Lowering, International Stroke Symposium, International Stroke Symposium CME invited Frankfurt Germany

- 10/2003 Endothelial Health and CV Events, Grand Rounds, University of New Mexico Invited
- 09/2003 Cardiovascular Disease and the Endothelium, VA Grand Rounds, VA Grand Rounds, Denver, CO CME invited
- 09/2003 Lipids and Interventional Cardiology, 24th Annual National Cardiology Meeting, 24th Annual National Cardiology Meeting, Lima, Peru CME invited
- 06/2003 Diabetes and Interventional Cardiology, University of Oklahoma Endocrine Grand Rounds, University of Oklahoma, Oklahoma City, Oklahoma CME Invited
- 12/2002 Statins Non Lipid Lowering Mechanisms, VA Hospital, VA Hospital, Grand Junction, CO CME invited
- 12/2002 Treatment for the Intermediate Risk Patient: Role of CRP, NY Symposium: Evolving Atherosclerosis Summit, NY Symposium: Evolving Atherosclerosis Summit CME invited
- 11/2002 The Vascular Wall: New Pathways and New Targets for treatment of cardiovascular disease, The Carolinas Heart Institute, VBWG CME invited grand rounds
- 11/2002 Emerging Role of Vascular Biology into Clinical Medicine: Focus on Lipids, AHA 2nd Annual Cardiology Fellows Forum of Excellence, American Heart Association 2nd Annual Cardiology Fellows Forum of Excellence CME invited
- 10/2002 Cardiology Update and Case Studies, ABIM Re-certification Course, American Board of Internal Medicine Washington University Health Science Center, Seattle Washington CME invited
- 10/2002 Clinical Pathways: The Role of Statins in the Treatment of Dyslipidemia: "Targeting the High Risk Patient", National AOA Symposium CME invited Meeting Chairman
- 10/2002 Prevention-Beyond the Acute Intervention, Baptist Health System Cardiovascular Update, Baptist Health System CME invited
- 10/2002 A inside Look at the Diabetic Vasculature, AAFP Scientific Assembly: National Diabetes Education Initiative, AAFP Scientific Assembly: National Diabetes Education Initiative CME invited
- 10/2002 Cardiovascular Disease in Patients with Type 2 Diabetes, AAFP Scientific Assembly: National Diabetes Education Initiative, AAFP Scientific Assembly: National Diabetes Education Initiative CME invited
- 10/2002 The Heart of Diabetics-Intravascular Ultrasound and Pathobiology, Cardiology Grand Rounds, Baptist Health South Florida Medical Center CME invited

- 09/2002 Noninvasive Workup of the Intermediate Risk patient, ACOI 62th Scientific Sessions, ACOI 62th Scientific Sessions CME invited & Chairman
- 09/2002 Power Point Presentation Work Shop-Advanced, ACOI 62th Scientific Sessions, ACOI 62th Scientific Sessions CME invited
- 09/2002 Coronary Artery Disease and Diabetes Mellitus, Texas Diabetes Institute, Texas Diabetes Institute CME invited
- 09/2002 Emerging Role of Statins Beyond LDL Reduction, Honolulu Heart Institute Annual Meeting CME Invited
- 09/2002 Heart Failure Update, Maui Medical Center Annual Symposium, Maui Medical Center Maui Hawaii, CME invited
- 09/2002 Hypertension and Atherosclerosis, Internal Medicine Grand Rounds Adventist Health System, Adventist Health System Oahu Hawaii CME invited
- 09/2002 Molecular Mechanism Of Statins, Medicine Grand Round, University of Hawaii, Hawaii CME invited
- 09/2002 Pathobiology of Acute Coronary Syndrome, Strabb Heart Institute, Strabb Heart Institute Oahu Hawaii CME invited
- 08/2002 Diagnosis and Treatment of Arrhythmias and Conduction Disorders, ACOI Medicine Board Review CME invited
- 06/2002 The Role of ACEI in Pathobiology of Hypertensive CV Disease, Hypertension Summit, Hong Kong, China CME invited
- 06/2002 Cardiovascular Disease Pathobiology to Clinical Medicine, Beijing Cardiovascular Institute, Beijing, China CME invited
- 06/2002 Role of ACEI in HT Disease, Taipei Cardiovascular Symposium, Taipei, China CME invited
- 06/2002 Secondary Prevention of Heart Disease: Role of Statins, CV Symposiums, Kabul, AF CME invited
- 06/2002 Cardiovascular Disease and Diabetes, Annual Medicine Symposium , Padre Valley Health System Padre Island CME invited
- 05/2002 Cardiology for the Boards-Review, San Antonio American College of Physicians Board Review, San Antonio ACP Board Review CME invited

- 03/2002 The Expanding Role of ARBs in Clinical Practice, International HT Symposium, San Juan, Puerto Rico CME invited
- 11/2001 Raising Expectations for new Therapies: Prevent the Event, AOA National Meeting: Symposium, Prevent the Event CME invited
- 11/2001 Endothelium and its Role in Atherosclerosis, AHA Cardiology Fellows Forum of Excellence, American Heart Association Cardiology Fellows Forum of Excellence (Keynote Speaker) CME invited
- 10/2001 Vascular Endothelium and Clinical Medicine, Medicine Grand Rounds, Kaoshung Medical School Kaoshung, China CME invited
- 10/2001 Targeting the Vascular Endothelium, International Meeting in Kaoshung, Sponsored by Kaoshung University, Kaoshung, China CME invited
- 10/2001 ACEI in CV Disease, Annual Hypertension Symposium, Taipei, China CME invited (Keynote Speaker) CME invited
- 10/2001 Cardiovascular Implications of Angiotensin II, Taiwan Regional Medical Center, Taipei, China CME invited
- 10/2001 The Role of IVUS in Diabetes Patients with Coronary Disease, The BARI-2D National Meeting Invited
- 10/2001 Role of Class III Anti arrhythmic Drugs in Treatment of Atrial Fibrillation, Southwest Regional Electrophysiology Meeting CME invited
- 09/2001 Advances in Understanding Vascular Disease: Role of Statins in Atherosclerosis-Keynote presentation, NY Lipid Symposium CME invited
- 08/2001 HT Treatment of the Complex CV Patient, NM State Medical Association Meeting Invited CME
- 06/2001 Inside th Diabetic Coronary Artery Treatment Considerations, Endocrine Grand Rounds, University of Oklahoma CME invited
- 05/2001 Hormone Replacement Therapy and CV Disease, Family Practice Annual Conference at UTHSCSA CME invited
- 05/2001 End Stage Cardiovascular Disease and Gene Therapy, International Invited Lecture, Heart Hospital of Hyderabad, India CME

- 05/2001 The Emerging Role of Diabetics in CV, International Lecture: 45th Annual Regional India Symposium on Cardiovascular New Delhi India CME invited
- 03/2001 Cardiovascular Treatment of Lipids-Statin Safety, Eastern Idaho Regional Medical Center, Eastern Idaho Regional Medical Center CME invited
- 12/2000 The Vascular Endothelium: Health and Disease, Grand Rounds Phoenix Arizona Heart Hospital CME invited
- 10/2000 Cardiovascular Effects of Training in Olympic Athletes-Role of the Endothelium, Symposium, Olympic Games (International Olympic Committee), Sydney, Australia (Keynote Address) Invited by Olympic Committee
- 09/2000 Cardiovascular Disease and Diabetes, Texas Diabetes Meeting UTHSCS CME invited
- 09/2000 Role of Beta Blockers in Ventricular Remodeling, PRIMED Meeting Boston Massachusetts CME invited
- 07/2000 Diabetes and Cardiovascular Disease, Endocrinology Grand Rounds at UT Galveston, UT Galveston CME Invited
- 07/2000 Emerging Role of Cardiology in Diabetes Patients, Cardiology Grand Rounds at UT Galveston, UT Galveston CME Invited
- 06/2000 Cardiovascular Disease and Case Studies, American Board of Internal Medicine Course Review, Washington University CME invited
- 06/2000 Endothelium a New Target for the Clinician, Canadian Heart Association Meeting Invited Keynote Address CME invited
- 05/2000 Treatment of Unstable Angina-New Treatment Guidelines, Montana Medical Association CME invited
- 05/2000 Hyperlipidemia and Treatment in Diabetics, National Puerto Rico Heart Association Meeting CME invited
- 05/2000 Role of the Endothelium in Clinical Practice, Honolulu, Hawaii National Straub Foundation Research Meeting CME invited
- 05/2000 TNK and the Acute MI, San Antonio Regional Acute Myocardial Infarction Symposium CME invited
- 04/2000 Angiotensin Receptors and clinical Practice, Oregon Medical Society Annual Meeting CME invited

- 04/2000 Hypertension in Review, AHA CV Task Force-Critical Care Nurses, AHA CV Task Force-Critical Care Nurses CME invited
- 04/2000 Interventions and the Endothelium, Interventional VBWG Regional Meeting, Interventional VBWG Regional Meeting CME invited
- 03/2000 New Guidelines: treatment of the Acute MI, Grand Rounds Brackenridge Hospital, Brackenridge Hospital CME invited
- 03/2000 Unstable and Stable Angina, National ACOI Board Review, National ACOI Board Review CME invited
- 03/2000 Practical implication to Vascular Biology in Clinical Cardiology, National Vascular Biology Working Group Meeting, National Vascular Biology Working Group Meeting CME invited
- 03/2000 Hypertension in Type 2 Diabetes, Annual Arizona Medical Association Meeting, Phoenix Arizona CME invited
- 03/2000 The Endothelium and Cardiovascular Drugs, 43rd National South African Cardiovascular Symposium, International Capetown, South Africa CME invited keynote address
- 03/2000 Treatment of Unstable Angina Aggressive vs Conservative Treatment, Durban National Cardiovascular Symposium, Durban, South Africa CME invited
- 03/2000 Vascular Biology and Cardiovascular Disease, Johannesburg Cardiology Symposium, Johannesburg South Africa CME invited
- 03/2000 Cardiovascular Disease and New Drugs, Medical Society of Zimbabwe Evening Symposium, Zimbabwe, Africa CME invited
- 03/2000 Endothelium and Oxidative Stress, Medicine Grand Rounds, Capetown University Medical Center, Capetown, South Africa CME invited
- 02/2000 Treatment of Chronic Stable Angina: New Guidelines, Medicine Grand Rounds, Texas Tech Health Science Center, CME invited
- 02/2000 Role of ARB and ACEI in Cardiovascular Disease, UCLA Medicine Grand Rounds, UCLA Los Angeles, California Invited
- 02/2000 The Role of ACEI and Heart Failure, Regional Heart Failure Symposium, VBWG Atlanta Georgia, CME invited

- 02/2000 Endothelium and Lipids A Clinical View, Annual Tri Cities Medicine Symposium South Padre Texas CME invited
- 02/2000 Preoperative Clearance for Non Cardiac Surgery in Cardiac Patients, Annual Midwinter Family Practice Symposium, Annual Midwinter Family Practice Symposium Texas Tech University CME invited
- 02/2000 Type II DM and Heart Disease, Texas Diabetes Institute Symposium UTHSCSA Division of Endocrinology CME invited
- 01/2000 Obesity and Cardiovascular Disease, The South Texas Obesity Symposium Austin Texas CME invited
- 01/2000 CV Disease and the Endothelium, Coalition for the Advancement of Cardiovascular Health National Meeting (COACH), Washington DC CME invited
- 01/2000 NEP inhibitors: Clinical Considerations for Cardiovascular Patients, Texas Cardiovascular Symposium, Dallas, TX CME invited
- 12/1999 Low Molecular Weight Heparin and the Cardiologist, Grand Rounds, Austin Heart Hospital, Austin, TX CME invited
- 12/1999 CV Disease the Role of the Endothelium, Athens University Medical Center, Athens, Greece CME invited
- 12/1999 Endothelium in Health and Disease, Symposium at Kapodistrian University of Athens Medical School University, Athens Greece CME invited
- 11/1999 Heart Failure and Endothelial Function, Saint Mary's Regional Medical Center, Saint Mary's Medical Center CME invited
- 11/1999 Clinical Applications of Endothelial Research, American Heart Association National Meeting, Vascular Biology Working Group Meeting CME invited
- 11/1999 Role of the RAA system in Endothelial Dysfunction, Cardiovascular Grand Rounds Chinese University Hong Kong Medical School, Hong Kong, China CME invited
- 10/1999 Antiarrhythmic Drugs and the Patient, UTHSCSA Anesthesia Grand Round, UTHSCSA, San Antonio, TX CME invited

- 10/1999 Secondary Prevention of CV Disease, National Thailand Heart Association Meeting, National Thailand Heart Association, Thailand CME invited
- 10/1999 The Endothelium and Vascular Disease, Cardiology Institute of Istanbul , Istanbul, Turkey CME invited
- 10/1999 Antiarrhythmic Drugs in Clinical Practice, Grand Rounds University of Washington Medical School Seattle Washington CME invited
- 10/1999 The Role of ACEI and ARB in Cardiovascular Disease, Vascular Biology Working Group Regional Symposium, CME invited
- 09/1999 Current Additions to JNC-VI Guidelines, Tucson Medical Center Grand Rounds, Tucson Medical Center Grand Rounds CME invited
- 09/1999 The Role of the Endothelium in CV Disease, Puerto Rico Cardiology Society National Meeting, CME invited
- 09/1999 The Role of Statins and the Endothelium, Lipid Symposium, Toronto, Canada CME invited
- 09/1999 Role of Lipids and the Endothelium, The Quebec Heart Institute, Quebec City, Canada CME invited
- 09/1999 The Endothelium and the Cardiovascular System, Medicine Grand Rounds, Ottawa Heart Institute CME invited
- 09/1999 Vascular Control by the Endothelium, Grand Rounds, McMaster University , Hamilton, Ontario, Canada CME invited
- 08/1999 Update on Positive Inotropes, AHA Nursing Task Force San Antonio Division, American Heart Association CME Invited
- 08/1999 Cardiovascular Disease and the Diabetic: The Role of the Endothelium, Boise Regional Medical Symposium, Boise Idaho CME invited
- 08/1999 Primary and Secondary Prevention of Heart Disease: Focus Unstable Plaque, Grand Rounds, JBH Medical Center, South Africa CME invited
- 08/1999 Role of the Endothelium in the Vulnerable Plaque, Medicine Grand Rounds, Capetown University, Capetown South Africa CME invited
- 08/1999 Endothelial Function in CV Disease, Medicine Grand Rounds, Tripler Army Hospital, Hawaii CME Invited

- 08/1999 Hyperlipidemia and Primary Prevention of Cardiovascular Disease, Medicine Grand Rounds, Kono Medical Center, Kono Hawaii CME invited
- 08/1999 Evaluation of the CV Disease in Dental Patients, University of Texas Dental School, University of Texas Dental School CME invited
- 08/1999 Type II Diabetes and Cardiovascular Disease, Medicine Grand Rounds, Chicago University Medical Center Chicago Illinois CME invited
- 08/1999 Role of Thrombolytic in the Treatment of the Acute MI, 5 County Medical Society Meeting South Padre Island, Texas CME invited
- 07/1999 The Role of Angiotensin Receptor Blockers in Clinical Practice, Medicine Grand Rounds Seattle Washington Medical Center, CME invited
- 07/1999 Cardiology for the Boards, American College of Physicians-University of Washington Health Science Center, Seattle, WA CME invited
- 06/1999 Current Evaluation and treatment of patients with wide complex tachycardia, Grand Rounds Cardiology, University of Taiwan Medical School, CME invited
- 06/1999 Role of the endothelium in Cardiovascular Disease, Medicine Grand Rounds Kaoshung Medical School, Kaoshung China CME invited
- 06/1999 Role of Statins in High Risk Patients, International Lipid Symposium, Durban, South Africa CME invited
- 06/1999 Beyond LDL lowering: Molicular Mechanism in Endothelial Stabilization, 34th Annual International Asian Heart Association Meeting, Asian Heart Association, Jakarta Pakistan CME Invited
- 06/1999 Role of ACEI in Cardiovascular Disease, Asian Cardiovascular Symposium, Bali, Indonesia CME invited
- 02/1999 Angiogenesis in Clinical Practice, Medicine Grand Rounds Philippine Heart Center, Quezon City, Philippines CME invited
- 12/1998 Markers of Inflammation: Is there a clinical role, Ottawa Heart Institute, Ottawa Heart Institute, CME invited
- 10/1998 Plaque Stabilization: Current Treatment Options, Grand Rounds Cardiology University of Thailand Medical Branch, Thailand CME invited

- 07/1998 Vascular Biology and Heart Disease, National Cardiology Symposium on Cardiovascular Disease, Karachi, Pakistan CME Invited
- 03/1998 Coronary Artery Disease Events and Plaque Biology, National Cardiovascular Symposium, Singapore CME invited
- 12/1997 Co-Shared Risk Factors for Endothelial Dysfunction and CV Disease, Cardiovascular Symposium, Istanbul , Turkey CME invited
- 07/1997 Endothelium and CV Disease: Focus on ACEI, National Cardiovascular Meeting, Riyadh, Saudi Arabia CME invited
- 07/1997 The Vascular Endothelium in Health and Disease, Angiotensin Converting Enzyme Inhibitor Symposium, Amman, Jordan CME invited
- 07/1997 Angiotensin Receptor Blockers vs ACEI Disease, Regional Hypertension Symposium, Petra, Jordan CME invited
- 07/1997 Heart Failure and Angiotensin Converting Enzyme Inhibitors, Regional Cardiovascular Symposium, Jerusalem, Palestine CME invited
- 01/1995 Women and heart disease, Teleconference Network, UTHSCSA, San Antonio, TX CME invited
- 12/1994 Small dense LDL Pattern B Syndrome, Medicine Grand Rounds, Brackenridge Hospital, Austin, TX CME invited
- 12/1994 HT in pilots- which agents are safe?, Grand Rounds, Randolph AFB Medical Group, San Antonio, TX CME invited
- 12/1994 Understanding New Antiarrhythmic Drugs: Amiodarone-Sotalol-Update, Southeast Medical Group, San Antonio Texas CME invited
- 12/1994 Congestive heart update, CHF workshop, Family Practice Grand Rounds, Brady Green Family Practice, UTHSCSA, San Antonio, TX CME invited
- 12/1994 Ventricular arrhythmia- which to treat, San Angles County Medical Society, San Angles County Medical Society CME invited
- 12/1994 Plaque Stabilization- is it possible?, Lubbock Medical Society Meeting, CME invited
- 11/1994 Evaluation of the arrhythmia patient, Medicine Grand Rounds. Brackenridge Hospital, Austin, TX CME invited

- 11/1994 Hypertension in the Hispanic Patient, African American/Hispanic Advisory Board. San Antonio Texas (Invited Speaker)
- 11/1994 Differentiation of HMG's, Medicine Grand Rounds Oklahoma State University. Tulsa, Oklahoma CME invited
- 11/1994 Sudden Death, Medicine Grand Rounds, University of Texas Health Science Center, San Antonio, TX CME invited
- 11/1994 Diabetes lipids and cardiovascular disease: which combinations are safe?, American College of Family Practice National Meeting CME Invited
- 10/1994 Cardiovascular Risk Reduction, Medicine Grand Rounds, Valley Diagnostic, Harlingen, Texas CME invited
- 10/1994 Current role of DDD pacemakers, Grand Rounds, Tucson Medial Center, Tucson, Arizona CME invited
- 10/1994 Cardiology Update. 20th Annual Mid American Medical Meeting, Kansas City, Kansas CME invited
- 10/1994 Current update on Supraventricular Arrhythmia, Medicine Grand Rounds. Beaumont Army Medical Center. El Paso Texas CME invited
- 10/1994 Use of Amiodarone, Midwestern Regional Medical Society CME invited
- 10/1994 Congestive Heart Failure Update, Teleconference Network, University of Texas Health Science Center, San Antonio, TX CME invited
- 09/1994 Management of CHF, Annual National Association of Managed Care Physicians. Dallas Texas CME invited
- 09/1994 Current Advances in Management of CHF: Timing for cardiac Transplant, Cardiology Update, Baptist Medical Center San Antonio Texas CME invited
- 08/1994 Treatment for the Minority Hypertensive, Annual New York Society of Family Practice Symposium CME invited
- 08/1994 Treatment Considerations with Elderly Hyperlipidemic Patients, Dallas Country Medical Society Dallas Texas CME invited
- 08/1994 Treatment of Atrial Fibrillation, Teleconference Network, University of Texas Health Science Center, San Antonio, TX CME invited

- 08/1994 Women and Heart Disease, Primary Care Forum, Teleconference Network of Texas
UTHSCSA CME invited
- 08/1994 Management and Evaluation of CV Disease in the Elderly, Annual Texas Society of Family
Practice Symposium CME invited
- 07/1994 Prevention of Target Organ Damage in Hypertensive Patients, Pinos Altos Medical Society.
Pinos Altos New Mexico CME invited
- 07/1994 Hypertensive Treatment Consideration in the Insulin Resistant Diabetic., Texas Tech Medical
Center, TX CME invited
- 07/1994 Emergency Treatment of Arrhythmias, Emergency Room Physicians, University of Texas
Health Science Center, San Antonio, TX CME invited
- 07/1994 Regression of Atherosclerosis with use of HMG's, Annual Lipid Symposium, Oklahoma
Medical Research Foundation, University of Oklahoma, Oklahoma City, Oklahoma CME
invited
- 07/1994 Atrial Arrhythmias Current Update, Medicine Grand Rounds, Brackenridge Hospital, Austin,
TX CME Invited
- 06/1994 Acute Myocardial Infarction, Grand Rounds Family Practice. University of Texas Health
Science Center CME invited
- 06/1994 CAD Plaque Stabilization, is it Possible?, Medicine Grand Rounds, Texas Tech Medical
School El Paso Texas CME invited
- 05/1994 Hypertension in the Diabetic, Annual Regional Valley Medical Conference, Harlingen, Texas
CME invited
- 05/1994 Post MI Treatment, Kerr County Medical Meeting Kerrville, Texas CME invited
- 04/1994 Cardiology Board Review-Park 1: Valvular Heart Disease, Part 2: Congenital Heart Disease,
Part 3: Electrophysiology Update, Part 4: Ischemic Heart Disease, Annual, American College
of Physician Review of Course UTHSCSA CME invited
- 04/1994 New Direction in Heart Failure, Clinical Relevance Tissue ACEI, International Heart Failure
Symposium Washington DC. CME invited
- 04/1994 Secondary Prevention: New Lipid guidelines, Medicine Grand Rounds, Kessler AFB Regional
Medical Center CME invited

- 04/1994 Lipid Chemistry Blood Test: Pattern B Syndrome, Teleconference Network, University of Texas Health Science Center, San Antonio, TX CME invited
- 04/1994 Secondary Prevention: Nutritional Modalities for regression of Atherosclerotic Plaques, Teleconference Network, University of Texas Health Science Center, San Antonio, TX CME invited
- 04/1994 Management of LV Dysfunction, New Jersey State Medical Meeting CME invited
- 04/1994 Hypertension in African, Hispanic, & Asian Pacific Patients, National Bureau for Coronary Artery Disease Risk. CME invited keynote address
- 04/1994 New Directions in Adult Treatment Panel, 14th Annual Meeting National Lipid Education Faculty CME invited
- 04/1994 Protection of the Hypertensive Diabetes Kidney, State Chest Hospital , San Antonio Texas CME invited
- 04/1994 Current Concepts in Secondary Prevention, Annual Lipid Meeting CME invited
- 03/1994 Case Studies in Cardiology, Update, The American Board of Internal Medicine UTHSCSA CME invited
- 03/1994 Signal Average EKG-Its Usefulness in Evaluating Patients for Cardiac Events, San Antonio Physicians Association CME invited
- 03/1994 Heart Disease-1994: Special Emphasis on Women, Annual Family Practice Review, University of Texas Health Science Center, San Antonio, TX CME invited
- 03/1994 Changing the Natural History of Coronary Artery Disease, Symposium Lecture, American College of Cardiology CME invited
- 03/1994 JNC-5-HT Recommendation, Teleconference Network of Texas, Eastern Regional Hypertension, St. Louis, MO CME invited
- 03/1994 Thrombolytics and the Acute Myocardial Infarction, Nevada State Medical Meeting Los Vegas Nevada CME invited
- 03/1994 Evaluation of Patients with Heart Murmurs, and Sudden Death, Annual family Practice Review Course UTHSCSA. CME invited
- 03/1994 Anti-arrhythmic Drugs-Current Trends, San Antonio Internal Medicine Society CME invited

- 02/1994 Women and Heart Disease, Tulsa Annual Regional Medical Meeting, Tulsa Oklahoma CME invited
- 02/1994 Current Treatment of Atrial Fibrillation, American College of Osteopathic Internist National Meeting CME invited
- 02/1994 Current HT Drugs, California Scientific Sessions Of Osteopathic Physicians and Surgeons CME invited
- 02/1994 Current Treatment of Ventricular Arrhythmias, Arizona State Medical Meeting CME invited
- 01/1994 LV Remodeling and the Human Heart, Northern California Medical Symposium, California CME invited
- 12/1993 New Directions in the Treatment of Ventricular Arrhythmias, Florida Regional Medical Meeting CME invited
- 11/1993 Role of Cellular Function in Ischemic Heart Disease, Annual California Medical Association Meeting CME invited
- 11/1993 Women and Heart Disease, Seventh Annual Michigan Medical Meeting, Notre Dame, University CME invited
- 10/1993 The Ischemic Left Ventricle-Treatment Options, Grand Rounds, University of North Texas Health Science Center Dallas Texas CME invited
- 10/1993 Practical evaluation of Lipid Disorders, Moderator and Lecture, American College of Family Physician Scientific Session, Boston, MA CME invited
- 09/1993 Update on Ischemic Heart Disease Treatment, Annual New Mexico Medical Association Meeting Albuquerque New Mexico CME invited
- 08/1993 Treatment of the Acute Myocardial Infarction in ICU, Critical Care Lecture, University of Texas Health Science Center, San Antonio, TX CME invited
- 08/1993 Coronary Artery Surgery vs PTCA, 44th Annual Assembly and Scientific Program of The Texas Academy of Family Physicians CME invited
- 08/1993 Molecular Cardiology-the Future, Baptist Medical Center San Antonio Texas CME invited
- 03/1993 Chronic Ischemic Heart Disease, ACGP Annual Meeting and Scientific Seminars CME invited
- 02/1993 Atrial Fibrillation- to treat or not to treat, Doctors Hospital 13th Annual Meeting Columbus Ohio CME invited

- 01/1993 CHD Risk Factor Reduction, Medicine Grand Rounds West Virginia Society of Medicine CME invited
- 01/1993 Treatment of Ischemic Heart Disease, TOMA District Meeting San Antonio Texas CME invited
- 01/1993 Anti-Arrhythmic Therapy in the Post-CAST Era, Hill Country County Medical Society San Antonio Texas CME invited
- 11/1992 Slow Pathway Tachycardias- Current Treatment, Cardiology Grand Rounds. University of Kansas Department of Medicine, Kansas City, Kansas CME invited
- 11/1991 Selected Factors in Hypertension, Medicine Grand Rounds, University of Missouri at Kansas City CME invited
- 10/1983 Cardiovascular Pharmacology, Medicine Grand Rounds. Methodist Hospital, San Antonio, TX CME invited
- 10/1983 Clinical Use of Calcium Channel Blockers, Mexican American Association, San Antonio, TX CME invited
- 09/1983 Modern Treatment of Hypertension, Medicine Grand Rounds, University of Texas Health Science Center. Houston, TX CME invited
- 09/1983 Cardiovascular Risks and Treatment of Angina, Medical Society, Bastrop, Texas CME invited
- 09/1983 Hypertension and Use of Calcium Blocker, Grand Rounds, University of Missouri at Kansas City Kansas CME invited
- 08/1983 Sudden Death, Medicine Grand Rounds, Brackenridge Hospital, Austin, TX CME invited
- 08/1983 Treatment of Cardiac Arrhythmias and Acute myocardial Infarction in Emergency Room, Alamo Area Emergency Room Physicians CME invited
- 07/1983 Management of Cardiac Patients in Flight, Kelly Air Force Base Cardiovascular Air Force Unit CME invited
- 07/1983 Advanced Life Support-Cardiac Dysrhythmia and DC Counter Shock, American Heart Association Invited
- 06/1983 Status of Heart Surgery, Mended Hearts Club (AHA)-Patients with Heart Surgery Local Chapter Invited

- 06/1983 Clinical Comparison of Beta Blockers and Calcium Blockers in Clinical Cardiology, Bexar County Medical Society San Antonio, Texas CME invited
- 05/1983 Sudden Cardiac Death, Cardiology Methodist Hospital, San Antonio, TX CME invited
- 04/1983 Cardiac Dysrhythmias, Mississippi Medical Association Annual Meeting, CME invited
- 04/1983 Cellular Myocardial Receptors in Clinical Practice of Cardiology, Cardiology Grand Rounds Kansas University Health Science Center CME invited
- 03/1983 Congestive Heart Failure and Ischemic Heart Disease, Kansas State Medical Association CME invited
- 03/1983 Management of Congestive Heart Failure and Hypertension, Texas Medical Association, Tyler, TX CME invited
- 03/1983 Clinical Usefulness of New Calcium Blockers, 6th District Texas Medical Association CME invited

SERVICE

SERVICE TO THE PROFESSION:

<u>Dates</u>	<u>Type Description</u>	<u>Role</u>
07/2002-Present	Nutrition, Physical Activity and metabolism (NPAM) American Heart Association	Member
	<i>Member</i>	
1993-2012	National Chairman, Clinical Cardiac Electrophysiology Examination Committee American College of Osteopathic Internist	Chairman
2011-Present	National Interventional cardiology board examination	Committee member
2005-2006	American Diabetes Association Program Planning Committee for macrovascular disease and lipids	Committee Member
2018- Present	Associate Editor Journal of Diabetes	
2007 - Present	Associate Editor of Practical Diabetology	
2010- Present	Associate Editor of Catheterization and Cardiovascular Interventions	
2011- Present	Deputy Editor of Clinical Diabetes (ADA)	
2012-Present	Editorial Board Diabetes Care	
2016-Present	Associate Editor Diabetes & Obesity International Journal	

2013-Present	Editorial Board of American Journal of Cardiology	
2013-Present	Editorial Board Journal of Cardiology and Cardiovascular Medicine (JCCM)	
2014-Present	Editorial Board Journal of Diabetes, Metabolic Disorders & Control	
2015-Present	Editorial Board: Cardiovascular Endocrinology	
2016-Present	Journal of Diabetes: Editorial board	
2012-Present	International Committee for Insulin Resistance (ICIR)	
07/2004-Present	Metabolism Clinical and Experimental	Journal Reviewer
1/1/2012-Present	Current Proteomics	Journal Reviewer
02/2006-Present	The Journal of Diabetes and Its Complications	Journal Reviewer
07/2007-Present	American Heart Journal	Journal Reviewer
01/2012-Present	Diabetes Care	Journal Reviewer
02/2012-Present	Diabetologia	Journal Reviewer
07/2002-Present	Diabetes Care	Journal Reviewer
07/2007-Present	Lipidology	Journal Reviewer
08/2007-Present	Obesity Research	Journal Reviewer
02/2012-Present	Expert Review of Clinical Pharmacology	Journal Reviewer
05/2010-Present	American Journal of Physiology- Heart and Circulatory	Journal Reviewer
08/2007-Present	Canadian Medical Association Journal	Journal Reviewer
03/2008-Present	American Journal of Cardiology	Journal Reviewer
03/2009-Present	Journal of Intensive Care Medicine	Journal Reviewer
08/2009-Present	Expert Review of Cardiovascular Therapy	Journal Reviewer
08/2008-Present	European Heart Journal	Journal Reviewer
09/2009-Present	The Journal of Clinical Hypertension	Journal Reviewer
03/2010-Present	Pharmacogenomics	Journal Reviewer
01/2018-Present	AJP: Heart and Circulatory Physiology	Journal Reviewer
<i>Reviewer</i>		
07/2002-Present	CV Digest	Journal Reviewer
05/2009-Present	Expert Review of Clinical Pharmacology	Journal Reviewer
<i>Editorial Board</i>		
2004 & present	International Examiner for a MD candidate registered at the Nelson R Mandela School of Medicine, University of KwaZulu Natal, South Africa	Examiner
<i>Health Education</i>		
01/1979-Present	Texas Medical Board of Examiners Texas Medical Foundation	Committee Member & Reviewer
<i>National</i>		
09/2000-Present	American Journal of Cardiology	Journal Reviewer
<i>Reviewer</i>		
07/1999-Present	National Diabetes Education Initiative	Committee Member

<i>Member</i>		
07/1997-Present	National Cholesterol Lipid Education Council	Committee Member
<i>Member</i>		
06/1992-Present	COACH Vascular Biology for Clinicians	Committee Member
<i>Member</i>		
07/1986-Present	American Osteopathic Board of Internal Medicine	Committee Member
<i>Member</i>		
07/1986-Present	Vascular Biology Working Group	Committee Member
<i>Member</i>		
7/2003-Present	Webmaster for American Heart Association NPAM website	Webmaster
<i>Health Education</i>		
7/2004-Present	Advocacy Ambassador for the NPAM council	Committee Member
3/2008-Present	IDOC Website Steering Committee	Committee Member
3/2008-Present	American Heart Association MMCC	Committee Member
	2011 ADA meeting Cardiology Section Chair	ADA
	2011 National ACOI/ AOA representative for Heart Failure Appropriateness Criteria	

SERVICE TO THE PUBLIC:

<u>Dates</u>	<u>Type Description</u>	<u>Role</u>
10/2002-10/2003	US Olympics Committee-Local	Member
<i>Member</i>		
07/2002-Present	American Heart Association	Regional and Affiliate Faculty for BLS and ACLS
<i>Advanced Life Support</i>		
07/1998-Present	University of Texas Chancellors Committee	Grants and Endowments
<i>Member</i>		

07/1988-Present	National Library Association	Grants and Endowment Committee
	<i>Member</i>	
07/1988-Present	Big Brother of America Association	Member
	<i>Member</i>	
07/1987-1988	San Antonio Cardiology Society	President
	<i>President</i>	
07/1986-Present	United Way	Member
	<i>Member</i>	
07/1985-07/1986	American Heart Association, San Antonio	President
	<i>President</i>	
07/1984-07/1985	American Heart Association, San Antonio Division	Chairman
	<i>Board of Directors</i>	
01/1983-Present	American Heart Association	Committee Member
	<i>Community</i>	

PROFESSIONAL AFFILIATIONS:

Dates

Organization

01/2000-Present	American Society of Hypertension
07/1997-Present	Member of Texas Cardiovascular Data Bank Committee
07/1997-Present	National Bureau Cardiovascular Risk Assessment Committee
07/1995-Present	Member of National Black/Hispanic Hypertension Committee
07/1986-Present	Teleconference Network of Texas
01/1986-Present	American College of Cardiology-Counsel member-Clinical Cardiology

1979-Present	American College of Osteopathic Internist
1975-Present	American Osteopathic Association
01/1986-Present	American College of Cardiology
01/1986-Present	North American Society of Pacing & Electrophysiology/Hearth Rhythm Society
01/1986-Present	American Heart Association

COMMITTEES (OTHER):

DEPARTMENT

<u>Dates</u>	<u>Committee</u>	<u>Role</u>
07/1990-Present	University of Texas Health Science Admission Board	Member

HOSPITAL

<u>Dates</u>	<u>Committee</u>	<u>Role</u>
03/2004-Present	Operative Risk Management Team, Audie L. Murphy VA Hospital	Member
06/2008-Present	Moderate Sedation Committee	Co-Chair
10/2003-Present	Cardiovascular Subcommittee P&T, University Hospital	Chair
07/2003-2008	Member Vision 17 Pharmacy and Therapeutics Committee VA, Veterans Association Hospital	Member
07/2003-2008	Veterans Association, Pharmacy and Therapeutics	Chair
07/2003-2008	Lipid subcommittee; Pharmacy and Therapeutics Committee VA, Veterans Association	Chair
01/1989-01/1991	Medicine, Baptist Memorial Hospital	Chair
07/1987-Present	Lipid Subcommittee of P and T, University Hospital	Member
01/1981-01/1983	Cardiology, Wilford Hall, USAF Medical Center	Associate Director
01/1979-01/1981	Electrophysiology Lab, Wilford Hall USAF Medical Center	Director
01/1979-01/1980	Coronary Care Unit, Wilford Hall USAF Medical Center	Director